Nucleic acid construct and use thereof

By optimizing the 5'UTR structure of the mRNA vaccine, especially by using a derivative sequence of the ARHGAP15 gene, the problem of insufficient UTR design in existing mRNA vaccines has been solved, achieving efficient regulation of target gene expression and improving vaccine stability and translation efficiency.

WO2023208118A9PCT designated stage expired Publication Date: 2024-11-28SHANGHAI REGENELEAD THERAPIES CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/091194
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-27
Filing Date
2023-04-27
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The UTR design and optimization of existing mRNA vaccines have not yet met the requirements for efficient regulation of target gene expression, affecting vaccine stability and translation efficiency.

Method used

Engineered 5' untranslated region elements (5'UTRs), such as the 5'UTR of the ARHGAP15 gene or its derivative sequences, are used to optimize the UTR structure through point mutations or truncation to enhance the ability to regulate the expression of the target gene.

Benefits of technology

Stable and efficient expression of the target gene was achieved, enhancing the clinical application potential of mRNA vaccines, especially showing excellent regulatory effects in influenza or COVID-19 vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023091194-FTAPPB-I100001
    Figure PCTCN2023091194-FTAPPB-I100001
  • Figure PCTCN2023091194-FTAPPB-I100002
    Figure PCTCN2023091194-FTAPPB-I100002
  • Figure PCTCN2023091194-FTAPPB-I100003
    Figure PCTCN2023091194-FTAPPB-I100003
Patent Text Reader

Abstract

The present disclosure relates to a nucleic acid construct and use thereof. Specifically, the present disclosure relates to a nucleic acid construct comprising an engineered UTR, and use thereof in the prevention and treatment of a disease (for example, prevention of virus infection). The UTR can significantly improve the expression efficiency of a target gene in the nucleic acid construct.
Need to check novelty before this filing date? Find Prior Art

Description

Nucleic acid constructs and their applications

[0001] This disclosure claims priority to the following patent application: Chinese patent application filed on April 27, 2022, with application number CN202210456261.9 and invention name “Nucleic Acid Constructs and Their Applications”; the entire contents of the above patent application are incorporated into this disclosure by reference. Technical Field

[0002] The present disclosure belongs to the field of nucleic acid drugs, and in particular relates to nucleic acid constructs comprising engineered UTRs and their use in preventing or treating diseases (eg, viral infections). Background Art

[0003] Vaccines are an important field of medical research. Existing vaccines include inactivated vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines, recombinant protein vaccines, and nucleic acid vaccines (including RNA vaccines and DNA vaccines). mRNA is the active ingredient of RNA vaccines, which mainly includes a cap structure (Cap), a 5' untranslated region (UTR), an open reading frame (ORF) encoding an antigen protein, a 3' UTR, and a poly (A) tail structure. Among them, the 5' UTR is the key to recruiting ribosomes to mRNA and initiating codon selection, and plays an important role in regulating translation efficiency and shaping the cell proteome (Ivanov, et al. Science. 2016, 352 (6292): 1413-1416.). The 3' UTR of eukaryotes has a variety of regulatory motifs that can be recognized by microRNAs (miRNAs) and rbp to control the stability, localization, and translation of mRNA (Mazumder et al., 2003; Mayr, 2017). The poly(A) tail (located at the 3' end of the mRNA) is another factor that determines mRNA stability and protein levels. The optional 3' UTR not only affects mRNA stability and translation but also controls mRNA localization (Tushev et al., 2018). The design and optimization of mRNA, especially the selection and use of its UTR, is a critical step in the entire mRNA vaccine product development process. Therefore, the development of efficient UTRs remains an urgent need in the field of mRNA pharmaceuticals.

[0004] The present disclosure provides an mRNA vaccine with a new UTR structure, which has the advantage of stable and efficient expression of the target gene. It can be universally applied to mRNA vaccines (for example, influenza or new coronavirus vaccines) to regulate the expression of the target gene and has excellent prospects for clinical drug application.

[0005] Summary of the Invention

[0006] The present disclosure provides nucleic acid elements and nucleic acid constructs that can regulate the expression of a target gene, wherein the nucleic acid construct comprises at least one nucleic acid element that can regulate the expression of a target gene.

[0007] Nucleic acid elements

[0008] In some embodiments, the nucleic acid element is a 5' untranslated region element (5'UTR).

[0009] In some embodiments, the 5'UTR is selected from the 5'UTR of any gene including Rho GTPase activating protein (ARHGAP), heat shock 27kDa protein 1 (HSPB1), hemoglobin subunit beta (HBB), chemokine cc-motif ligand 13 (CCL13), or a derivative sequence thereof.

[0010] In some embodiments, the 5'UTR in the nucleic acid construct is derived from or is a 5'UTR sequence of an ARHGAP gene or a derivative thereof. In some embodiments, the ARHGAP includes ARHGAP1, ARHGAP2, ARHGAP3, ARHGAP4, ARHGAP5, ARHGAP6, ARHGAP7 (DLC1), ARHGAP8, ARHGAP9, ARHGAP10, ARHGAP12, ARHGAP13 (SRGAP1), ARHGAP14 (SRGAP2), ARHGAP15, ARHGAP17 (RICH1), ARHGAP18, ARHGAP19, ARHGAP20, ARHGAP21, ARHGAP22, ARHGAP23, ARHGAP24, ARHGAP25, ARHGAP26.

[0011] In some embodiments, the 5'UTR is derived from or is a 5'UTR sequence of the ARHGAP15 gene or a derivative thereof. In some embodiments, the ARHGAP15 gene is derived from any species, such as human ARHGAP15, baboon ARHGAP15, monkey ARHGAP15, mouse ARHGAP15, etc.

[0012] In some embodiments, the 5'UTR is derived from or is a 5'UTR sequence of the human ARHGAP15 gene or a derivative thereof. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO: 1 or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0013] In some embodiments, the 5'UTR comprises at least one point mutation that can be used to inhibit translation initiation from an ATG within the UTR. In some embodiments, the point mutation is selected from a mutation at any one or more of A, T, or G in the ATG sequence in the 5'UTR. In some embodiments, the point mutation is a mutation at the A site of the ATG sequence in the 5'UTR. In some embodiments, the mutation is a mutation from A to G, C, or T. In some embodiments, the mutation is a mutation from A to GTG, CTG, or TTG. Further, the mutation can be used to inhibit translation initiation from an ATG within the UTR.

[0014] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene contains at least one point mutation that can be used to inhibit translation initiation at the ATG within the UTR. In some embodiments, the point mutation is selected from mutations at any one or more of A, T, or G within the ATG sequence in the 5'UTR. In some embodiments, the point mutation is a mutation at the A site of the ATG sequence in the 5'UTR. In some embodiments, the mutation is an A to G, C, or T mutation.

[0015] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises the nucleotide sequence shown in SEQ ID NO: 44, or the 5'UTR comprises a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 44, wherein N1 is selected from A, G, C, or T.

[0016] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which ATG is mutated to GTG. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 2, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0017] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which ATG is mutated to CTG. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 42, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0018] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which ATG is mutated to TTG. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 43, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0019] In some embodiments, the 5'UTR is a 5'UTR truncation. In some embodiments, the 5'UTR truncation still retains similar functional activities as the native 5'UTR, such as still retaining the function of regulating the ORF to encode the target gene protein. In some embodiments, the 5'UTR truncation has enhanced functional activities compared to the native 5'UTR, such as enhanced function of regulating the ORF to encode the target gene protein.

[0020] In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and / or, deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end. In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end, while retaining the nucleotide sequence at the 3' end. In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end, while retaining the nucleotide sequence at the 5' end. In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end. In some embodiments, the 5'UTR truncation method further comprises a point mutation according to any of the foregoing embodiments. In some embodiments, the 5'UTR truncation does not comprise the point mutation of any of the foregoing embodiments. In some embodiments, the 5'UTR truncation retains at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% of the length of the native 5'UTR sequence.

[0021] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises or is an ARHGAP15 5'UTR truncation. In some embodiments, the truncation comprises deleting a continuous nucleotide sequence at the 5' end from the 5' end to the 3' end of the ARHGAP15 5'UTR; and / or deleting a continuous nucleotide sequence at the 3' end from the 3' end to the 5' end of the sequence.

[0022] In some embodiments, the truncation method comprises deleting a continuous nucleotide sequence at the 5' end from the 5' to the 3' end of the ARHGAP15 5'UTR, and retaining the nucleotide sequence at the 3' end. In some embodiments, the truncation method of the 5'UTR truncation comprises deleting a continuous nucleotide sequence at the 3' end from the 3' to the 5' end of the ARHGAP15 5'UTR, and retaining the nucleotide sequence at the 5' end. In some embodiments, the truncation method of the 5'UTR truncation comprises deleting a continuous nucleotide sequence at the 5' end from the 5' to the 3' end of the ARHGAP15 5'UTR; and, in the sequence direction from the 3' to the 5' end, deleting a continuous nucleotide sequence at the 3' end.

[0023] In some embodiments, the truncation retains at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% of the length of the native ARHGAP15 5'UTR (SEQ ID NO: 1).

[0024] In some embodiments, the 5'UTR truncation comprises at least 5 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 2 or 44; in some embodiments, the 5'UTR truncation comprises 5-62 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 2 or 44; in some embodiments, the 5'UTR truncation comprises 7-62 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 2 or 44; in some embodiments, the 5'UTR truncation comprises 7-59 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 2; illustratively, the 5'UTR truncation comprises SEQ ID NO: 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 consecutive nucleotide sequences of the sequence shown in NO: 2 or 44.

[0025] In some embodiments, the nucleotide at the 5' terminus of the 5'UTR truncation (i.e., the starting nucleotide of the 5'UTR truncation) is a nucleotide at any position 1-57 of the sequence shown in SEQ ID NO: 2 or 44, according to natural numbering. In some embodiments, the nucleotide at the 5' terminus of the 5'UTR truncation is a nucleotide at any position 1-13 or 17-29 of the sequence shown in SEQ ID NO: 2 or 44, according to natural numbering. 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105

[0026] For example, the nucleotides at the 5' end of the 5'UTR truncation and the length of the continuous nucleotide sequence in the sequence shown in SEQ ID NO: 2 contained in the 5'UTR truncation are shown in the following table:

[0027] In some embodiments, the length of the 5'UTR truncation is 59 bp, 55 bp, 51 bp, 47 bp, 43 bp, 39 bp, 35 bp, 31 bp, 27 bp, 23 bp, 19 bp, 15 bp, 11 bp, or 7 bp.

[0028] In some embodiments, the ARHGAP15 5'UTR truncation further comprises a point mutation according to any of the aforementioned embodiments. In some embodiments, the ARHGAP15 5'UTR truncation further comprises a nucleotide sequence in which ATG is mutated to GTG. In some embodiments, the 5'UTR derived from the ARHGAP15 gene comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 28-30, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0029] In some embodiments, the ARHGAP15 5'UTR truncation does not comprise the point mutation of any of the aforementioned embodiments. In some embodiments, the 5'UTR of the aforementioned ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO:31-40, comprising CTATAAT; or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any of the aforementioned sequences.

[0030] In some embodiments, the 5'UTR truncation comprises at least CTATAAT or the nucleotide sequence shown in SEQ ID NO: 193.

[0031] In some embodiments, the ARHGAP15 5'UTR truncation comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 41, 76, 137-196, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0032] In some embodiments, the 5'UTR derived from the HSPB1 gene comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 3-5, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with any one of SEQ ID NOs: 3-5.

[0033] In some embodiments, the 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-2, 3-5, 28-43, 76, 137-196, or the following sequence: CTATAAT, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the foregoing sequences.

[0034] Nucleic acid constructs

[0035] The present disclosure provides a nucleic acid construct comprising:

[0036] (a) open reading frame (ORF); and

[0037] (b) 5' untranslated region element (5'UTR).

[0038] In some embodiments, the ORF is a polynucleotide sequence encoding a target gene protein.

[0039] In some embodiments, the gene of interest is heterologous. In other embodiments, the gene of interest is endogenous.

[0040] In some embodiments, the 5'UTR in the nucleic acid construct is located upstream of the open reading frame. In some embodiments, the 5'UTR in the nucleic acid construct is located at the 5' end of the open reading frame.

[0041] In some embodiments, the 5'UTR in the nucleic acid construct is selected from or is the 5'UTR of any gene such as Rho GTPase activating protein (ARHGAP), heat shock 27kDa protein 1 (HSPB1), β-globin (hemoglobin subunit beta, HBB), chemokine cc-motif ligand 13 (CC motif chemokine ligand 13, CCL13) or a derivative sequence thereof.

[0042] In some embodiments, the 5'UTR in the nucleic acid construct is derived from or is a 5'UTR sequence of an ARHGAP gene or a derivative thereof. In some embodiments, the ARHGAP includes ARHGAP1, ARHGAP2, ARHGAP3, ARHGAP4, ARHGAP5, ARHGAP6, ARHGAP7 (DLC1), ARHGAP8, ARHGAP9, ARHGAP10, ARHGAP12, ARHGAP13 (SRGAP1), ARHGAP14 (SRGAP2), ARHGAP15, ARHGAP17 (RICH1), ARHGAP18, ARHGAP19, ARHGAP20, ARHGAP21, ARHGAP22, ARHGAP23, ARHGAP24, ARHGAP25, ARHGAP26.

[0043] In some embodiments, the 5'UTR in the nucleic acid construct is derived from or is the 5'UTR sequence of the ARHGAP15 gene or a derivative thereof. In some embodiments, the ARHGAP15 gene is derived from any species, such as human ARHGAP15, baboon ARHGAP15, monkey ARHGAP15, mouse ARHGAP15, etc.

[0044] In some embodiments, the 5'UTR in the nucleic acid construct is derived from or is the 5'UTR sequence of the human ARHGAP15 gene or a derivative thereof. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 1 or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0045] In some embodiments, the 5'UTR in the nucleic acid construct comprises at least one point mutation that can be used to inhibit the initiation of translation from ATG within the UTR. In some embodiments, the point mutation is selected from a mutation at any one or more of A, T, or G in the ATG sequence in the 5'UTR. In some embodiments, the point mutation is a mutation at the A site of the ATG sequence in the 5'UTR. In some embodiments, the mutation is a mutation from A to G, C, or T. In some embodiments, the mutation is a mutation from A to GTG, CTG, or TTG. Further, the mutation can be used to inhibit the initiation of translation from ATG within the UTR.

[0046] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene contains at least one point mutation that can be used to inhibit translation initiation at the ATG within the UTR. In some embodiments, the point mutation is selected from mutations at any one or more of A, T, or G within the ATG sequence in the 5'UTR. In some embodiments, the point mutation is a mutation at the A site of the ATG sequence in the 5'UTR. In some embodiments, the mutation is an A to G, C, or T mutation.

[0047] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises the nucleotide sequence shown in SEQ ID NO: 44, or the 5'UTR comprises a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 44, wherein N1 is selected from A, G, C, or T.

[0048] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which ATG is mutated to GTG. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 2, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0049] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which ATG is mutated to CTG. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 42, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0050] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which ATG is mutated to TTG. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 43, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0051] In some embodiments, the 5'UTR in the nucleic acid constructs of the present disclosure is a 5'UTR truncation. In some embodiments, the 5'UTR truncation still retains similar functional activities as the native 5'UTR, such as still retaining the function of regulating the ORF to encode the expression of the target gene protein. In some embodiments, the 5'UTR truncation has enhanced functional activities compared to the native 5'UTR, such as enhanced function of regulating the ORF to encode the target gene protein.

[0052] In some embodiments, the truncation of the 5'UTR truncation comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and / or, deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end. In some embodiments, the truncation of the 5'UTR truncation comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end, while retaining the nucleotide sequence at the 3' end. In some embodiments, the truncation of the 5'UTR truncation comprises: deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end, while retaining the nucleotide sequence at the 5' end. In some embodiments, the truncation of the 5'UTR truncation comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and, the truncation of the 5'UTR truncation comprises: deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end.

[0053] In some embodiments, the 5'UTR truncation further comprises a point mutation according to any of the preceding embodiments. In some embodiments, the 5'UTR truncation does not comprise a point mutation according to any of the preceding embodiments. In some embodiments, the 5'UTR truncation retains at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% of the length of the native 5'UTR sequence.

[0054] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises or is an ARHGAP15 5'UTR truncation. In some embodiments, the truncation comprises deleting a continuous nucleotide sequence at the 5' end from the 5' end to the 3' end of the ARHGAP15 5'UTR; and / or deleting a continuous nucleotide sequence at the 3' end from the 3' end to the 5' end of the sequence.

[0055] In some embodiments, the truncation method comprises deleting a continuous nucleotide sequence at the 5' end from the 5' to the 3' end of the ARHGAP15 5'UTR, and retaining the nucleotide sequence at the 3' end. In some embodiments, the truncation method of the 5'UTR truncation comprises deleting a continuous nucleotide sequence at the 3' end from the 3' to the 5' end of the ARHGAP15 5'UTR, and retaining the nucleotide sequence at the 5' end. In some embodiments, the truncation method of the 5'UTR truncation comprises deleting a continuous nucleotide sequence at the 5' end from the 5' to the 3' end of the ARHGAP15 5'UTR; and, in the sequence direction from the 3' to the 5' end, deleting a continuous nucleotide sequence at the 3' end.

[0056] In some embodiments, the truncation retains at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% of the length of the native ARHGAP15 5'UTR (SEQ ID NO: 1).

[0057] In some embodiments, the 5'UTR truncation comprises at least 5 consecutive nucleotide sequences in the nucleotide sequence of SEQ ID NO: 2 or 44; in some embodiments, the 5'UTR truncation comprises 5-62 consecutive nucleotide sequences in the sequence of SEQ ID NO: 2 or 44; in some embodiments, the 5'UTR truncation comprises 7-62 consecutive nucleotide sequences in the sequence of SEQ ID NO: 2 or 44; in some embodiments, the 5'UTR truncation comprises 7-59 consecutive nucleotide sequences in the sequence of SEQ ID NO: 2; illustratively, the 5'UTR truncation comprises SEQ ID NO: 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 consecutive nucleotides of the sequence shown in NO: 2.

[0058] In some embodiments, the nucleotide at the 5' terminus of the 5'UTR truncation (i.e., the starting nucleotide of the 5'UTR truncation) is a nucleotide at any position 1-57 of the sequence shown in SEQ ID NO: 2 or 44, according to natural numbering. In some embodiments, the nucleotide at the 5' terminus of the 5'UTR truncation is a nucleotide at any position 1-13 or 17-29 of the sequence shown in SEQ ID NO: 2 or 44, according to natural numbering. 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105

[0059] For example, the nucleotides at the 5' end of the 5'UTR truncation and the length of the continuous nucleotide sequence in the sequence shown in SEQ ID NO: 2 contained in the 5'UTR truncation are shown in the following table:

[0060] In some embodiments, the length of the 5'UTR truncation is 59 bp, 55 bp, 51 bp, 47 bp, 43 bp, 39 bp, 35 bp, 31 bp, 27 bp, 23 bp, 19 bp, 15 bp, 11 bp, or 7 bp.

[0061] In some embodiments, the ARHGAP15 5'UTR truncation further comprises a point mutation according to any of the aforementioned embodiments. In some embodiments, the ARHGAP15 5'UTR truncation further comprises a nucleotide sequence in which ATG is mutated to GTG. In some embodiments, the 5'UTR derived from the ARHGAP15 gene comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 28-30, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0062] In some embodiments, the ARHGAP15 5'UTR truncation does not comprise the point mutation of any of the aforementioned embodiments. In some embodiments, the 5'UTR of the aforementioned ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO: 31-40, CTATAAT, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0063] In some embodiments, the 5'UTR truncation comprises at least CTATAAT or the nucleotide sequence shown in SEQ ID NO: 193.

[0064] In some embodiments, the ARHGAP15 5'UTR truncation comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 41, 76, 137-196, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0065] In some embodiments, the 5'UTR derived from the HSPB1 gene comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 3-5, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity with any one of SEQ ID NOs: 3-5.

[0066] In some embodiments, the 5'UTR in the nucleic acid construct of the present disclosure comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-2, 3-5, 28-43, 76, 137-196, or a sequence as shown below: CTATAAT; or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0067] In some specific embodiments, the 5'UTR of any of the above nucleic acid constructs comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-5, 28-43, 76, 137-196, or the following sequence: CTATAAT.

[0068] In some embodiments, the disclosed nucleic acid construct further comprises: (c) a 3' untranslated region element (3'UTR).

[0069] In some embodiments, the open reading frame and the 5'UTR and / or the 3'UTR of the present disclosure are derived from different genes. In some embodiments, the nucleic acid construct of the present disclosure comprises at least one open reading frame, at least one 5'UTR, or at least one 3'UTR. In some embodiments, the 5'UTR and 3'UTR in the nucleic acid construct of the present disclosure are derived from the same or different sources, for example, from the same or different genes. In some embodiments, the 5'UTR and 3'UTR in the nucleic acid construct of the present disclosure are derived from the same species or different species.

[0070] In some embodiments, the 3'UTR in the nucleic acid construct of the present disclosure is located downstream of the open reading frame. In some embodiments, the 3'UTR in the nucleic acid construct is located at the 3' end of the open reading frame.

[0071] In some embodiments, the 3'UTR in the nucleic acid construct of the present disclosure is selected from or is a 3'UTR or a derivative sequence thereof of any gene such as hemoglobin subunit beta (HBB), ARHGAP15, coronin 1A (CORO1A), hemopexin (HPX), etc.

[0072] In some embodiments, the 3'UTR is derived from or is the 3'UTR sequence of the HBB or ARHGAP15 gene or a derivative thereof.

[0073] In some embodiments, the 3'UTR derived from the HBB gene comprises or is the nucleotide sequence shown in SEQ ID NO: 7 or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0074] In some embodiments, the 3'UTR derived from the ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO: 8, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0075] In some embodiments, the 3'UTR derived from the CORO1A gene comprises or is the nucleotide sequence shown in SEQ ID NO: 9 or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0076] In some embodiments, the 3'UTR derived from the HPX gene comprises or is the nucleotide sequence shown in SEQ ID NO: 10, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0077] In some embodiments, the 3'UTR in the nucleic acid construct of the present disclosure comprises or is a nucleotide sequence as set forth in any one of SEQ ID NOs: 7-10, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto. In some specific embodiments, the 3'UTR comprises or is a nucleotide sequence as set forth in SEQ ID NOs: 7 or 8.

[0078] In some embodiments, the nucleic acid construct comprises a 5'UTR and a 3'UTR, wherein:

[0079] The 5'UTR is selected from or is the 5'UTR or a derivative sequence thereof of any gene such as ARHGAP (eg ARHGAP15), HSPB1, HBB, CCL13, etc., and the 3'UTR is selected from or is the 3'UTR or a derivative sequence thereof of any gene such as HBB, ARHGAP15, CORO1A, HPX, etc.

[0080] In some embodiments, the nucleic acid construct comprises a 5'UTR and a 3'UTR, and the 5'UTR and the 3'UTR are selected from any one of the following:

[0081] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0082] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0083] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof;

[0084] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a derivative sequence thereof;

[0085] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0086] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0087] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof;

[0088] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a derivative sequence thereof;

[0089] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0090] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0091] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof;

[0092] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a derivative sequence thereof; or

[0093] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0094] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0095] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof; or

[0096] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a sequence derived therefrom, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a sequence derived therefrom.

[0097] In some embodiments, the nucleic acid construct of the present disclosure comprises a 5'UTR and a 3'UTR, wherein the 5'UTR and the 3'UTR are selected from any one of the following:

[0098] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 1-2, 28-43, 76, 137-196, CTATAAT, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 7, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0099] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 1-2, 28-43, 76, 137-196, CTATAAT, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 8, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0100] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 1-2, 28-43, 76, 137-196, CTATAAT, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 9, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0101] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 1-2, 28-43, 76, 137-196, CTATAAT, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 10, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0102] The 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:3, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:7, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0103] The 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:3, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:8, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0104] The 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:3, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:9, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0105] The 5'UTR comprises or is the nucleotide sequence of SEQ ID NO: 3, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 10, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0106] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:4, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:7, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0107] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:4, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:8, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0108] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:4, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:9, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0109] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:4, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:10, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0110] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:5, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:7, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0111] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:5, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:8, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0112] The 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:5, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:9, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0113] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:5, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:10, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0114] In some embodiments, the nucleic acid construct comprises a 5'UTR and a 3'UTR, wherein:

[0115] The 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-2, 28-43, 76, 137-196, and CTATAAT, and the 3'UTR is derived from or is a 3'UTR derived from HBB, ARHGAP15, CORO1A, HPX gene or a derivative sequence thereof.

[0116] In some specific embodiments, the nucleic acid construct comprises a 5'UTR and a 3'UTR, wherein:

[0117] The 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-2, 28-43, 76, 137-196, and CTATAAT, and the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 7-10.

[0118] In some embodiments, the nucleic acid construct of the present disclosure further comprises: (d) a polyadenylic acid (poly-A) tail.

[0119] In some embodiments, the poly-A tail in the nucleic acid construct is located downstream of the 3' UTR. In some embodiments, the poly-A tail in the nucleic acid construct is located at the 3' end of the 3' UTR. In some embodiments, the poly-A tail is at the 3' end of the nucleic acid construct. In some embodiments, the poly-A tail is at least about 50, 100, 150, 200, 300, 400, or 500 nucleotides in length.

[0120] In some embodiments, the poly-A tail includes but is not limited to HGH polyA, SV40 polyA, BGH polyA, rbGlob polyA, or SV40late polyA.

[0121] In some specific embodiments, the poly-A tail comprises or is the nucleotide sequence shown in SEQ ID NO: 16 or 135.

[0122] In some embodiments, from the 5' to 3' direction, the nucleic acid construct as described in any one of the above items contains any one of i)-iv):

[0123] i) 5'UTR, and open reading frame (ORF);

[0124] ii) open reading frame (ORF), and 3'UTR;

[0125] iii) 5'UTR, open reading frame (ORF), and 3'UTR;

[0126] iv) 5'UTR, open reading frame (ORF), 3'UTR, and poly-A tail;

[0127] The ORF and the 5'UTR and / or the 3'UTR are derived from different genes.

[0128] In some embodiments, the 5'UTR in i), iii) to iv) is selected from the 5'UTR derived from any gene such as ARHGAP, HSPB1, HBB, CCL13, or a derivative thereof (eg, the 5'UTR of ARHGAP15 or a derivative thereof).

[0129] In some embodiments, the 3'UTR in ii) to iv) is selected from the 3'UTR derived from any gene such as HBB, ARHGAP15, CORO1A, HPX, or a derivative thereof (eg, the 3'UTR of HBB or ARHGAP15 or a derivative thereof).

[0130] In some embodiments, the poly-A tail in iv) to iv) comprises a nucleotide sequence such as shown in SEQ ID NO: 16 or 135.

[0131] In some embodiments, the 5'UTR in i) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-5, 28-43, 76, 137-196, or CTATAAT.

[0132] In some embodiments, the 3'UTR in ii) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 7-10.

[0133] In some embodiments, the 5'UTR in iii) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-5, 28-43, 76, 137-196, or CTATAAT, and the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 7-10.

[0134] In some embodiments, the 5'UTR in iv) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-5, 28-43, 76, 137-196, or CTATAAT, the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 7-10, and the poly-A tail comprises or is a nucleotide sequence as shown in SEQ ID NOs: 16 or 135.

[0135] In the present disclosure, in any of the above nucleic acid constructs, the ORF comprises a nucleotide sequence encoding at least one polypeptide or protein. In some embodiments, the nucleotide sequence may be a codon-optimized nucleotide sequence.

[0136] In some embodiments, the polypeptide or protein encoded by the ORF is a fluorescent protein or luciferase.

[0137] In some embodiments, the polypeptide or protein encoded by the ORF is a viral antigen. For example, the viral antigen includes, but is not limited to, antigens of influenza virus, coronavirus, respiratory syncytial virus, human immunodeficiency virus, herpes simplex virus, rabies virus, or Epstein-Barr virus.

[0138] In some embodiments, the viral antigen is a coronavirus antigen. In some embodiments, the coronavirus is a coronavirus that infects humans, such as SARS-CoV-2 (COVID-19), SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, or MERS-CoV. In some embodiments, the coronavirus is SARS-COV-2. In some embodiments, the coronavirus antigen is a structural protein. In some embodiments, the structural protein is selected from spike protein (S protein or Spike protein), envelope protein (E protein), membrane protein (M protein), and nucleocapsid protein (N protein). In some embodiments, the structural protein is a spike protein. In some embodiments, the spike protein is SARS-COV-2 spike protein. In some embodiments, the SARS-COV-2 spike protein is selected from the spike protein of any virus strain such as SARS-COV-2 (e.g., wild-type SARS-COV-2), SARS-COV-2Alpha (B.1.1.7), SARS-COV-2Beta (B.1.351), SARS-COV-2Gamma (P.1), SARS-COV-2Kappa (B.1.617.1), SARS-COV-2Delta (B.1.617.2), SARS-COV-2Omicron (B.1.1.529), and SARS-COV-2Omicron (BA4).

[0139] In some embodiments, the SARS-COV-2 spike protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 12, 14, 21, 23, 25, 80, 136, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto.

[0140] In some embodiments, the ORF comprises a codon-optimized nucleotide sequence comprising a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a wild-type nucleotide sequence encoding a SARS-COV-2 antigen (e.g., wild-type SARS-COV-2, SEQ ID NO: 81).

[0141] In some embodiments, the ORF encoding the polypeptide or protein comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 13, 15, 20, 22, 24, 81, 97, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0142] In some embodiments, the ORF encodes an influenza virus antigen. In some embodiments, the influenza virus is selected from influenza A virus or influenza B virus, illustratively, the influenza virus is influenza A virus H1N1, influenza A virus H3N2, influenza A virus H3N8, influenza A virus H2N2, influenza A virus H5N1, influenza A virus H9N2, influenza A virus H7N7, influenza B virus / Victoria (e.g., influenza B virus / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), etc. In some embodiments, the influenza virus antigen is a structural protein of influenza virus, for example, hemagglutinin (HA), neuraminidase (NA), ion channel protein M2 (M2 ion channel), matrix protein M1 (matrix protein), nucleoprotein NP (nucleoprotein), etc. In some specific embodiments, the influenza virus antigen is the HA protein of influenza virus, such as influenza A virus H1N1, influenza A virus H3N2, influenza B virus Victoria (e.g., Influenza B / Washington / 02 / 2019), and influenza B virus Yamagata (e.g., Influenza B / Phuket / 3073 / 2013). In some specific embodiments, the influenza virus antigen is the NA protein of influenza virus, such as influenza A virus H1N1, influenza A virus H3N2, influenza B virus Victoria (e.g., Influenza B / Washington / 02 / 2019), and influenza B virus Yamagata (e.g., Influenza B / Phuket / 3073 / 2013).

[0143] In some embodiments, the HA protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 83-86, 98-101, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto.

[0144] In some embodiments, the ORF comprises a codon-optimized nucleotide sequence comprising a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a wild-type nucleotide sequence encoding an HA antigen.

[0145] In some embodiments, the ORF comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 87-90, 102-105, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0146] In some embodiments, the ORF comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 93-96, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0147] In some embodiments, the present disclosure provides a nucleic acid construct comprising, from 5' to 3' direction, a 5'UTR, an ORF, a 3'UTR, and a poly-A tail. In some embodiments, the 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 1-5, 28-43, 76, 137-196, or CTATAAT, the ORF comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 13, 15, 20, 22, 24, 81, 97, 87-90, 93-96, or 102-105, the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 7-10, and the poly-A tail comprises or is a nucleotide sequence as shown in SEQ ID NOs: 16 or 135.

[0148] Illustratively, the nucleic acid construct comprises the nucleotide sequence shown in SEQ ID NO: 18-19.

[0149] In the present disclosure, including any embodiment thereof, the nucleic acid construct is a nucleic acid molecule, such as cDNA.

[0150] RNA molecules

[0151] The present disclosure provides an RNA molecule comprising:

[0152] (a) open reading frame (ORF); and

[0153] (b) 5' untranslated region element (5'UTR).

[0154] In some embodiments, the ORF is a polynucleotide sequence encoding a target gene protein.

[0155] In some embodiments, the gene of interest is heterologous. In other embodiments, the gene of interest is endogenous.

[0156] In some embodiments, the 5'UTR in the RNA molecule is located upstream of the open reading frame. In some embodiments, the 5'UTR in the RNA molecule is located at the 5' end of the open reading frame.

[0157] In some embodiments, the 5'UTR in the RNA molecule is selected from or is the 5'UTR of any gene such as Rho GTPase activating protein (ARHGAP), heat shock 27kDa protein 1 (HSPB1), β-globin (hemoglobin subunit beta, HBB), chemokine cc-motif ligand 13 (CC motif chemokine ligand 13, CCL13) or a derivative sequence thereof.

[0158] In some embodiments, the 5'UTR in the RNA molecule is derived from or is a 5'UTR sequence of an ARHGAP gene or a derivative thereof. In some embodiments, the ARHGAP includes ARHGAP1, ARHGAP2, ARHGAP3, ARHGAP4, ARHGAP5, ARHGAP6, ARHGAP7 (DLC1), ARHGAP8, ARHGAP9, ARHGAP10, ARHGAP12, ARHGAP13 (SRGAP1), ARHGAP14 (SRGAP2), ARHGAP15, ARHGAP17 (RICH1), ARHGAP18, ARHGAP19, ARHGAP20, ARHGAP21, ARHGAP22, ARHGAP23, ARHGAP24, ARHGAP25, ARHGAP26.

[0159] In some embodiments, the 5'UTR is derived from or is the 5'UTR sequence of the ARHGAP15 gene or a derivative thereof. In some embodiments, the ARHGAP15 gene is derived from any species, such as human ARHGAP15, baboon ARHGAP15, mouse ARHGAP15, etc.

[0160] In some embodiments, the 5'UTR is derived from or is the 5'UTR sequence of the human ARHGAP15 gene or a derivative thereof. In some embodiments, the 5'UTR of the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 45 or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0161] In some embodiments, the 5'UTR in the RNA molecules of the present disclosure comprises at least one point mutation, including the point mutation in any of the aforementioned nucleic acid constructs. In some embodiments, the mutation is an A to G, C, or U mutation.

[0162] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises the nucleotide sequence shown in SEQ ID NO: 79, or the 5'UTR comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 79, wherein N2 is selected from A, G, C, or U.

[0163] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which AUG is mutated to GUG. In some embodiments, the 5'UTR derived from the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 46, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0164] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which AUG is mutated to CUG. In some embodiments, the 5'UTR derived from the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 77, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0165] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises a nucleotide sequence in which AUG is mutated to UUG. In some embodiments, the 5'UTR derived from the ARHGAP15 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 78, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0166] In some embodiments, the 5'UTR in the RNA molecules of the present disclosure is a 5'UTR truncation. In some embodiments, the 5'UTR truncation still retains similar activity functions as the native 5'UTR, for example, still retains the function of regulating the expression of the protein encoded by the ORF of the target gene.

[0167] In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and / or, deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end. In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end, while retaining the nucleotide sequence at the 3' end. In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end, while retaining the nucleotide sequence at the 5' end. In some embodiments, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and, the 5'UTR truncation method comprises: deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end. In some embodiments, the 5'UTR truncation method further comprises a point mutation according to any of the foregoing embodiments. In some embodiments, the 5'UTR truncation does not comprise the point mutation of any of the foregoing embodiments. In some embodiments, the 5'UTR truncation retains at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% of the length of the native 5'UTR sequence.

[0168] In some embodiments, the aforementioned 5'UTR sequence derived from the ARHGAP15 gene comprises or is an ARHGAP15 5'UTR truncation. In some embodiments, the truncation comprises deleting a continuous nucleotide sequence at the 5' end from the 5' end to the 3' end of the ARHGAP15 5'UTR; and / or deleting a continuous nucleotide sequence at the 3' end from the 3' end to the 5' end of the sequence.

[0169] In some embodiments, the truncation method comprises deleting a continuous nucleotide sequence at the 5' end from the 5' to the 3' end of the ARHGAP15 5'UTR, and retaining the nucleotide sequence at the 3' end. In some embodiments, the truncation method of the 5'UTR truncation comprises deleting a continuous nucleotide sequence at the 3' end from the 3' to the 5' end of the ARHGAP15 5'UTR, and retaining the nucleotide sequence at the 5' end. In some embodiments, the truncation method of the 5'UTR truncation comprises deleting a continuous nucleotide sequence at the 5' end from the 5' to the 3' end of the ARHGAP15 5'UTR; and, in the sequence direction from the 3' to the 5' end, deleting a continuous nucleotide sequence at the 3' end.

[0170] In some embodiments, the truncation retains at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% of the length of the native ARHGAP15 5'UTR (SEQ ID NO: 45).

[0171] In some embodiments, the 5'UTR truncation comprises at least 5 consecutive nucleotide sequences of the nucleotide sequence shown in SEQ ID NO: 46 or 79; in some embodiments, the 5'UTR truncation comprises 5-62 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 46 or 79; in some embodiments, the 5'UTR truncation comprises 7-62 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 46 or 79; in some embodiments, the 5'UTR truncation comprises 7-59 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 46 or 79; illustratively, the 5'UTR truncation comprises SEQ ID NO: 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 consecutive nucleotides of the sequence shown in NO: 2.

[0172] In some embodiments, the nucleotide at the 5' terminus of the 5'UTR truncation (i.e., the starting nucleotide of the 5'UTR truncation) is a nucleotide at any position 1-57 of the sequence shown in SEQ ID NO: 46 or 79, according to natural numbering. In some embodiments, the nucleotide at the 5' terminus of the 5'UTR truncation is a nucleotide at any position 1-13 or 17-29 of the sequence shown in SEQ ID NO: 46 or 79, according to natural numbering. 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105

[0173] In some embodiments, the length of the 5'UTR truncation is 59 bp, 55 bp, 51 bp, 47 bp, 43 bp, 39 bp, 35 bp, 31 bp, 27 bp, 23 bp, 19 bp, 15 bp, 11 bp, or 7 bp.

[0174] In some embodiments, the ARHGAP15 5'UTR truncation further comprises a point mutation according to any of the aforementioned embodiments. In some embodiments, the ARHGAP15 5'UTR truncation further comprises a nucleotide sequence in which AUG is mutated to GUG. In some embodiments, the 5'UTR derived from the ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO: 63-65, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0175] In some embodiments, the ARHGAP15 5'UTR truncation does not comprise the point mutation of any of the aforementioned embodiments. In some embodiments, the aforementioned 5'UTR derived from the ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO: 66-75, CUAUAAU, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0176] In some embodiments, the aforementioned 5'UTR derived from the ARHGAP15 gene comprises or is a sequence corresponding to the sequence shown in SEQ ID NO: 41, 76, 137-196 (T in the sequence is replaced by U), or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0177] In some embodiments, the 5'UTR derived from the HSPB1 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 47, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0178] In some embodiments, the 5'UTR derived from the HBB gene comprises or is the nucleotide sequence shown in SEQ ID NO: 48, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0179] In some embodiments, the 5'UTR derived from the CCL13 gene comprises or is the nucleotide sequence shown in SEQ ID NO: 49, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0180] In some embodiments, the 5'UTR in the RNA molecule of the present disclosure comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 63-75, 77-78, CUAUAAU, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto. Alternatively, the 5'UTR in the RNA molecule comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, 137-196 (with U replacing T in the sequence), or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0181] In some specific embodiments, the 5'UTR of any of the above RNA molecules comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 63-75, 77-78, or CUAUAAU. Alternatively, the 5'UTR of the RNA molecule comprises a sequence corresponding to a sequence as shown in SEQ ID NOs: 41, 76, or 137-196 (with T in the sequence replaced by U).

[0182] In some embodiments, the disclosed RNA molecules further comprise: (c) a 3' untranslated region element (3'UTR).

[0183] In some embodiments, the open reading frame and the 5'UTR and / or the 3'UTR of the present disclosure are derived from different genes. In some embodiments, the RNA molecules of the present disclosure comprise at least one open reading frame, at least one 5'UTR, or at least one 3'UTR. In some embodiments, the 5'UTR and 3'UTR of the RNA molecules of the present disclosure are derived from the same or different sources, for example, from the same or different genes. In some embodiments, the 5'UTR and 3'UTR of the RNA molecules of the present disclosure are derived from the same or different species.

[0184] In some embodiments, the 3'UTR in the RNA molecules of the present disclosure is located downstream of the open reading frame. In some embodiments, the 3'UTR in the RNA molecules of the present disclosure is located at the 3' end of the open reading frame. In some embodiments, the 3'UTR in the RNA molecules of the present disclosure is selected from or is a 3'UTR of any gene such as hemoglobin subunit beta (HBB), ARHGAP15, coronin 1A (CORO1A), hemopexin (HPX), or a derivative thereof.

[0185] In some embodiments, the 3'UTR is derived from or is the 3'UTR sequence of the HBB or ARHGAP15 gene or a derivative thereof.

[0186] In some embodiments, the 3'UTR derived from the HBB gene comprises or is the nucleotide sequence shown in SEQ ID NO: 50, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0187] In some embodiments, the 3'UTR derived from the ARHGAP15 gene comprises or is a nucleotide sequence as shown in SEQ ID NO: 51 or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0188] In some embodiments, the 3'UTR derived from the CORO1A gene comprises or is the nucleotide sequence shown in SEQ ID NO: 52, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0189] In some embodiments, the 3'UTR derived from the HPX gene comprises or is the nucleotide sequence shown in SEQ ID NO: 53, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0190] In some embodiments, the 3'UTR in the disclosed RNA molecules comprises or is a nucleotide sequence as set forth in any one of SEQ ID NOs: 50-53, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0191] In some specific embodiments, the 3'UTR comprises or is a nucleotide sequence as shown in SEQ ID NO: 50 or 51.

[0192] In some embodiments, the RNA molecule comprises a 5'UTR and a 3'UTR, wherein:

[0193] The 5'UTR is selected from or is the 5'UTR or a derivative sequence thereof of any gene such as ARHGAP (eg ARHGAP15), HSPB1, HBB, CCL13, etc., and the 3'UTR is selected from or is the 3'UTR or a derivative sequence thereof of any gene such as HBB, ARHGAP15, CORO1A, HPX, etc.

[0194] In some embodiments, the RNA molecule comprises a 5'UTR and a 3'UTR, and the 5'UTR and the 3'UTR are selected from any one of the following:

[0195] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0196] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0197] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof;

[0198] The 5'UTR is derived from or is the 5'UTR of the ARHGAP15 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a derivative sequence thereof;

[0199] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0200] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0201] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof;

[0202] The 5'UTR is derived from or is the 5'UTR of the HBB gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a derivative sequence thereof;

[0203] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0204] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0205] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof;

[0206] The 5'UTR is derived from or is the 5'UTR of the HSPB1 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a derivative sequence thereof; or

[0207] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the HBB gene or a derivative sequence thereof;

[0208] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the ARHGAP15 gene or a derivative sequence thereof;

[0209] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a derivative sequence thereof, and the 3'UTR is derived from or is the 3'UTR of the CORO1A gene or a derivative sequence thereof; or

[0210] The 5'UTR is derived from or is the 5'UTR of the CCL13 gene or a sequence derived therefrom, and the 3'UTR is derived from or is the 3'UTR of the HPX gene or a sequence derived therefrom.

[0211] In some embodiments, the RNA molecule of the present disclosure comprises a 5'UTR and a 3'UTR, wherein the 5'UTR and the 3'UTR are selected from any one of the following:

[0212] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 45-46, 63-75, 77-78, CUAUAAU, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, or the 5'UTR comprises a sequence corresponding to SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U), or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto; and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 50, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0213] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 45-46, 63-75, 77-78, CUAUAAU, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, or the 5'UTR comprises a sequence corresponding to SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U), or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto; and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 51, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0214] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 45-46, 63-75, 77-78, CUAUAAU, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, or the 5'UTR comprises a sequence corresponding to SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U), or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto; and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 52, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0215] The 5'UTR comprises or is the nucleotide sequence of any one of SEQ ID NOs: 45-46, 63-75, 77-78, CUAUAAU, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, or the 5'UTR comprises a sequence corresponding to SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U), or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto; and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO: 53, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0216] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:47, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:50, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0217] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:47, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:51, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0218] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:47, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:52, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0219] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:47, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:53, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0220] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:48, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:50, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0221] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:48, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:51, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0222] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:48, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:52, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0223] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:48, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:53, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0224] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:49, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:50, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0225] the 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:49, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:51, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0226] The 5'UTR comprises or is the nucleotide sequence of SEQ ID NO:49, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence of SEQ ID NO:52, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0227] the 5'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:49, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto, and the 3'UTR comprises or is the nucleotide sequence set forth in SEQ ID NO:53, or a nucleotide sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto;

[0228] In some embodiments, the RNA molecule comprises a 5'UTR and a 3'UTR, wherein:

[0229] The 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-46, 63-75, 77-78, and CUAUAAU, or the 5'UTR comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, and 137-196 (T in the sequence is replaced by U); and the 3'UTR is derived from or is the 3'UTR of any one of the genes HBB, ARHGAP15, CORO1A, and HPX, or a derivative sequence thereof.

[0230] In some specific embodiments, the RNA molecule comprises a 5'UTR and a 3'UTR, wherein:

[0231] The 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-46, 63-75, 77-78, CUAUAAU, or the 5'UTR comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U); and the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 50-53.

[0232] In some embodiments, the RNA molecules of the present disclosure further comprise: (d) a polyadenylic acid (poly-A) tail.

[0233] In some embodiments, the poly-A tail in the RNA molecule is located downstream of the 3' UTR. In some embodiments, the poly-A tail in the RNA molecule is located at the 3' end of the 3' UTR. In some embodiments, the poly-A tail is at the 3' end of the RNA molecule. In some embodiments, the poly-A tail is at least about 50, 100, 150, 200, 300, 400, or 500 nucleotides in length.

[0234] In some embodiments, the poly-A tail includes but is not limited to HGH polyA, SV40 polyA, BGH polyA, rbGlob polyA, or SV40late polyA.

[0235] In some specific embodiments, the poly-A tail comprises or is the nucleotide sequence shown in SEQ ID NO: 56 or 135.

[0236] In some embodiments, the RNA molecules of the present disclosure further comprise: (e) a 5' cap structure (5'Cap).

[0237] In some embodiments, the 5' cap structure in the RNA molecule is located upstream of the 5' UTR. In some embodiments, the 5' cap structure in the RNA molecule is located at the 5' end of the 5' UTR. In some embodiments, the 5' cap structure is a cap structure known to those skilled in the art, such as Cap0 (methylation of the first nucleobase, for example, m7GpppN), Cap1 (additional methylation of the ribose of the adjacent nucleotide of m7GpppN, for example, m7G(5')ppp(5')(2'OMeA)pG), Cap2 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), Cap3 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), Cap4 (additional methylation of the ribose of the fourth nucleotide downstream of m7GpppN), ARCA (anti-reverse cap analog), modified ARCA (for example, phosphorothioate-modified ARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine and 2-azido-guanosine.

[0238] In some embodiments, the 5'-cap structure (eg, Cap0 or Cap1) is formed using chemical RNA synthesis or in vitro transcription of RNA (co-transcriptional capping).

[0239] In some embodiments, a capping enzyme (e.g., vaccinia virus capping enzyme and / or cap-dependent 2'-O methyltransferase) is used to form a 5'-cap structure (e.g., Cap0 or Cap1) via enzymatic capping. In some embodiments, an immobilized capping enzyme is used to add the 5' cap structure (Cap0 or Cap1). The capping methods and means described in WO2016 / 193226 are incorporated herein in their entirety.

[0240] In some embodiments, the 5' cap structure includes but is not limited to ARCA, 3'OMe-m7G(5')ppp(5')G, m7G(5')ppp(5')(2'OMeA)pU, m7Gppp(A2'O-MOE)pG, m7G(5')ppp(5')(2'OMeA)pG, m7G(5')ppp(5')(2'OMeG)pG, m7(3'OMeG)(5')ppp(5')(2'OMeG)pG or m7(3'OMeG)(5')ppp(5')(2'OMeA)pG.

[0241] In some specific embodiments, the 5' cap structure is m7G(5')ppp(5')(2'OMeA)pG. Other 5' cap structures or cap structure analogs can also be used.

[0242] In some embodiments, from the 5' to 3' direction, the RNA molecule of any of the above items contains any one of i)-v):

[0243] i) 5'UTR, and open reading frame (ORF);

[0244] ii) open reading frame (ORF), and 3'UTR;

[0245] iii) 5'UTR, open reading frame (ORF), and 3'UTR;

[0246] iv) 5'UTR, open reading frame (ORF), 3'UTR, and poly-A tail;

[0247] v) 5' cap structure (5'Cap), 5'UTR, open reading frame (ORF), 3'UTR, and poly-A tail;

[0248] The ORF and the 5'UTR and / or the 3'UTR are derived from different genes.

[0249] In some embodiments, the 5'UTR in i), iii) to v) is selected from the 5'UTR derived from any gene such as ARHGAP, HSPB1, HBB, CCL13, or a derivative thereof (eg, the 5'UTR of ARHGAP15 or a derivative thereof).

[0250] In some embodiments, the 3'UTR in ii) to v) is selected from the 3'UTR derived from any gene such as HBB, ARHGAP15, CORO1A, HPX, or a derivative thereof (eg, the 3'UTR of HBB or ARHGAP15 or a derivative thereof).

[0251] In some embodiments, the poly-A tail in iv) to v) comprises a nucleotide sequence such as that shown in SEQ ID NO:56.

[0252] In some embodiments, the 5' cap structure in v) includes but is not limited to Cap0, Cap1 (eg, m7G(5')ppp(5')(2'OMeA)pG), Cap2, Cap3, Cap4, and ARCA.

[0253] In some embodiments, the 5'UTR in i) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 63-75, 77-78, and CUAUAAU; or, the 5'UTR comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, and 137-196 (T in the sequence is replaced by U).

[0254] In some embodiments, the 3'UTR in ii) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 50-53.

[0255] In some embodiments, the 5'UTR in iii) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 63-75, 77-78, CUAUAAU, or the 5'UTR comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U); and the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 50-53.

[0256] In some embodiments, the 5'UTR in iv) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 63-75, 77-78, CUAUAAU, or the 5'UTR comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U); the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 50-53, and the poly-A tail comprises or is a nucleotide sequence as shown in SEQ ID NO: 56.

[0257] In some embodiments, the 5'UTR in v) comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 63-75, 77-78, CUAUAAU, or the 5'UTR comprises a sequence corresponding to the sequence shown in SEQ ID NOs: 41, 76, 137-196 (T in the sequence is replaced by U); the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 50-53, the poly-A tail comprises or is a nucleotide sequence as shown in SEQ ID NO: 56, and the 5' cap structure is m7G(5')ppp(5')(2'OMeA)pG.

[0258] In the present disclosure, in any of the above-mentioned RNA molecules, the ORF comprises a nucleotide sequence encoding at least one polypeptide or protein. In some embodiments, the nucleotide sequence may be a codon-optimized nucleotide sequence.

[0259] In some embodiments, the polypeptide or protein encoded by the ORF is a fluorescent protein or luciferase.

[0260] In some embodiments, the polypeptide or protein encoded by the ORF is a viral antigen. For example, the viral antigen includes, but is not limited to, antigens of influenza virus, coronavirus, respiratory syncytial virus, human immunodeficiency virus, herpes simplex virus, rabies virus, or Epstein-Barr virus.

[0261] In some embodiments, the viral antigen is a coronavirus antigen. In some embodiments, the coronavirus is a coronavirus that infects humans, such as SARS-CoV-2 (COVID-19), SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, or MERS-CoV. In some embodiments, the coronavirus is SARS-COV-2. In some embodiments, the coronavirus antigen is a structural protein. In some embodiments, the structural protein is selected from spike protein (S protein or Spike protein), envelope protein (E protein), membrane protein (M protein), and nucleocapsid protein (N protein). In some embodiments, the structural protein is a spike protein. In some embodiments, the spike protein is SARS-COV-2 spike protein. In some embodiments, the SARS-COV-2 spike protein is selected from the spike protein of any virus strain such as SARS-COV-2 (e.g., wild-type SARS-COV-2), SARS-COV-2Alpha (B.1.1.7), SARS-COV-2Beta (B.1.351), SARS-COV-2Gamma (P.1), SARS-COV-2Kappa (B.1.617.1), SARS-COV-2Delta (B.1.617.2), SARS-COV-2Omicron (B.1.1.529), and SARS-COV-2Omicron (BA.4). In some embodiments, the SARS-COV-2 spike protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 12, 14, 21, 23, 25, 80, 136, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto.

[0262] In some embodiments, the ORF comprises a codon-optimized nucleotide sequence comprising a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a wild-type nucleotide sequence encoding a SARS-COV-2 antigen (e.g., wild-type SARS-COV-2, SEQ ID NO: 82).

[0263] In some embodiments, the ORF encoding the polypeptide or protein comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 54-55, 59-61, 82, 130, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0264] In some embodiments, the ORF encodes an influenza virus antigen. In some embodiments, the influenza virus is selected from influenza A virus or influenza B virus, illustratively, the influenza virus is influenza A virus H1N1, influenza A virus H3N2, influenza A virus H3N8, influenza A virus H2N2, influenza A virus H5N1, influenza A virus H9N2, influenza A virus H7N7, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), etc. In some embodiments, the influenza virus antigen is a structural protein of influenza virus, for example, hemagglutinin (HA), neuraminidase (NA), ion channel protein M2 (M2 ion channel), matrix protein M1 (matrix protein), nucleoprotein NP (nucleoprotein), etc. In some specific embodiments, the influenza virus antigen is the HA protein of influenza virus, such as influenza A virus H1N1, influenza A virus H3N2, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013). In some specific embodiments, the influenza virus antigen is the NA protein of influenza virus, such as influenza A virus H1N1, influenza A virus H3N2, influenza B virus Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus Yamagata (e.g., Influenza B / Phuket / 3073 / 2013). In some embodiments, the HA protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 83-86, 98-101, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto.

[0265] In some embodiments, the ORF comprises a codon-optimized nucleotide sequence comprising a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a wild-type nucleotide sequence encoding an HA antigen.

[0266] In some embodiments, the ORF encoding the polypeptide or protein comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 126-129, 131-134, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0267] In some embodiments, the present disclosure provides an RNA molecule comprising, from 5' to 3' direction, a 5'UTR, an ORF, a 3'UTR, and a poly-A tail. In some embodiments, the 5'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 45-49, 45-49, 63-75, 77-78, and CUAUAAU, or the 5'UTR comprises a sequence corresponding to a sequence as shown in SEQ ID NOs: 41, 76, or 137-196 (with T in the sequence replaced by U); the ORF comprises or is a nucleotide sequence as shown in SEQ ID NOs: 54-55, 59-61, 82, or 126-134, the 3'UTR comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 50-53, and the poly-A tail comprises or is a nucleotide sequence as shown in SEQ ID NOs: 56 or 135. In some specific embodiments, the RNA molecule comprises a nucleotide sequence as shown in SEQ ID NOs: 57-58, or 106-125.

[0268] In the present disclosure, including any embodiments thereof, the RNA molecule may be mRNA.

[0269] The present disclosure uses for the first time a 5'UTR sequence derived from human Rho GTPase activating protein (ARHGAP) for the recombinant expression of a target gene (such as a SARS-CoV-2 viral protein), and screens, designs, and successfully verifies that the 5'UTR derived from ARHGAP15 5'UTR and its modified 5'UTR can initiate efficient expression of different target genes. Rho GTPase activating protein 15 (ARHGAP15) belongs to the ARHGAP family and is a Rac1-specific GTPase activating protein (GAPs), which is the main negative regulator of Rho family GTPase activity. The present disclosure provides more 5'UTR and 3'UTR selections and combinations with excellent expression efficiency, and at the same time, provides an mRNA vaccine with the potential to effectively prevent new coronavirus infection and influenza virus infection, especially for its various variants.

[0270] polynucleotides

[0271] The present disclosure also provides an isolated polynucleotide encoding one or more polypeptides or proteins, wherein the polypeptide or protein is a coronavirus antigen. In some embodiments, the coronavirus is SARS-COV-2. In some embodiments, the coronavirus antigen is a structural protein. In some embodiments, the structural protein is selected from spike protein (S protein or Spike protein), envelope protein (E protein), membrane protein (M protein) and nucleocapsid protein (N protein). In some embodiments, the structural protein is a spike protein. In some embodiments, the spike protein is a SARS-COV-2 spike protein. In some embodiments, the SARS-COV-2 spike protein is selected from the spike protein of any virus strain such as SARS-COV-2 (e.g., wild-type SARS-COV-2), SARS-COV-2Alpha (B.1.1.7), SARS-COV-2Beta (B.1.351), SARS-COV-2Gamma (P.1), SARS-COV-2Kappa (B.1.617.1), SARS-COV-2Delta (B.1.617.2), SARS-COV-2Omicron (B.1.1.529), and SARS-COV-2Omicron (BA.4). In some embodiments, the SARS-COV-2 spike protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 12, 14, 21, 23, 25, 80, 136, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto.

[0272] In some embodiments, the ORF encodes an influenza virus antigen. In some embodiments, the influenza virus is selected from influenza A virus or influenza B virus, illustratively, the influenza virus is influenza A virus H1N1, influenza A virus H3N2, influenza A virus H3N8, influenza A virus H2N2, influenza A virus H5N1, influenza A virus H9N2, influenza A virus H7N7, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), etc. In some embodiments, the influenza virus antigen is a structural protein of influenza virus, for example, hemagglutinin (HA), neuraminidase (NA), ion channel protein M2 (M2 ion channel), matrix protein M1 (matrix protein), nucleoprotein NP (nucleoprotein), etc. In some specific embodiments, the influenza virus antigen is the HA protein of influenza virus, such as influenza A virus H1N1, influenza A virus H3N2, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013). In some specific embodiments, the influenza virus antigen is the NA protein of influenza virus, such as influenza A virus H1N1, influenza A virus H3N2, influenza B virus Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus Yamagata (e.g., Influenza B / Phuket / 3073 / 2013). In some embodiments, the influenza virus HA protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 83-86, 98-101, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto.

[0273] In some embodiments, the ORF comprises a codon-optimized nucleotide sequence comprising a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a wild-type nucleotide sequence encoding a SARS-COV-2 antigen (e.g., wild-type SARS-COV-2 mRNA, SEQ ID NO: 82).

[0274] In some embodiments, the isolated polynucleotide comprises or is a nucleotide sequence as shown in SEQ ID NO: 54-55, 59-61, 82, 126-134, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0275] In some embodiments, the polynucleotide is RNA, such as mRNA. In some embodiments, the polynucleotide is an ORF region of mRNA.

[0276] In some embodiments, the present disclosure provides the use of any of the aforementioned nucleic acid constructs or RNA molecules in any of the following: (1) preparing a vaccine; (2) encoding a viral antigen in a subject or in vitro; (3) preparing a drug that encodes a viral antigen in a subject or in vitro; (4) for preparing a drug.

[0277] In some embodiments, the nucleic acid construct or RNA molecule of the present disclosure encodes a protein of interest, wherein the open reading frame (ORF) has enhanced expression of the protein of interest.

[0278] Modification

[0279] To further improve the stability of protein expression of the RNA or polynucleotide molecules of the present disclosure, the RNA or polynucleotide molecules may further comprise one or more modifications (including chemical modifications), such as backbone modifications, sugar modifications, base modifications, and / or lipid modifications. In some embodiments, the RNA or polynucleotide molecules are uniformly modified to a particular modification (e.g., completely modified throughout the sequence). For example, the RNA can be uniformly modified with pseudouridine such that every U in the sequence is a pseudouridine.

[0280] The backbone modification relevant to the present disclosure refers to the chemical modification of the phosphate of the backbone of the nucleotide included in the RNA or polynucleotide molecule of the present disclosure. In some embodiments, the backbone modification includes but is not limited to completely replacing the unmodified phosphate part in the backbone with the modified phosphate, for example, the phosphate group of the backbone can be modified by replacing one or more oxygen atoms with different substituents. In some embodiments, the modified phosphate includes but is not limited to phosphorothioate, phosphite selenate, borane phosphate, borane phosphate, hydrogen phosphonate, phosphoramidate, alkyl or aryl phosphonate and phosphotriester.

[0281] Sugar modifications relevant to the present disclosure refer to chemical modifications of the sugars of the nucleotides contained in the RNA or polynucleotide molecules of the present disclosure. In some embodiments, the sugar modifications include but are not limited to modifying or replacing the 2' hydroxyl (OH) of the RNA molecule with many different "oxy" or "deoxy" substituents. In some embodiments, the "oxy" modifications include but are not limited to substitution modifications of alkoxy, aryloxy, polyethylene glycol (PEG) and the like. In some embodiments, "deoxy" modifications include but are not limited to hydrogen, amino (e.g., NH2, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino or amino acid) modifications.

[0282] Base modification relevant to the present disclosure refers to the chemical modification of the base portion of the nucleotide contained in the RNA or polynucleotide molecule of the present disclosure. In some embodiments, the base modification includes the modification of adenine, guanine, cytosine and uracil in the nucleotide. For example, the nucleosides and nucleotides described herein can be chemically modified on the main groove surface. In some embodiments, the main groove chemical modification can include amino, thiol, alkyl or halogen groups. In some embodiments, the base modification includes but is not limited to modification with pseudouridine, 1-methyl-pseudouridine, 5-azacytidine, 5-methylcytosine-5'-triphosphate or 2-methoxyadenine. In some embodiments, the base modification is pseudouridine modification. In some specific embodiments, RNA can be uniformly modified with pseudouridine so that each U in the sequence is a pseudouridine.

[0283] Lipid modification in connection with the present disclosure refers to the inclusion of lipid modification in the RNA or polynucleotide molecules of the present disclosure. In some embodiments, the lipid modification includes but is not limited to the covalent attachment of the RNA or polynucleotide molecules of the present disclosure to at least one linker, and the covalent attachment of the corresponding linker to at least one lipid. In some embodiments, the lipid modification includes but is not limited to the covalent attachment of the RNA or polynucleotide molecules of the present disclosure to at least one lipid (without a linker).

[0284] UTRs

[0285] UTRs (5'UTR and / or 3'UTR) can be provided as flanking regions to nucleic acid constructs, RNA or polynucleotide molecules of the present disclosure. UTRs can be homologous or heterologous to the coding regions in nucleic acid constructs, RNA or polynucleotide molecules of the present disclosure. Flanking regions can comprise one or more 5'UTRs and / or 3'UTRs, and the UTRs can be identical or different sequences. Any portion of the flanking regions can be codon optimized. Before and / or after codon optimization, any portion of the flanking regions can independently comprise one or more different structures or chemical modifications.

[0286] In order to change one or more characteristics of the nucleic acid construct, RNA or polynucleotide of the present invention, UTRs heterologous to the ORF of the present invention are introduced or engineered into the nucleic acid construct, RNA or polynucleotide of the present invention. The recombinant nucleic acid construct, RNA or polynucleotide is then applied to a cell, tissue or organism, and the results, such as protein levels, localization and / or half-life, are measured to assess the beneficial effects of the heterologous UTR on the RNA or polynucleotide of the present invention. In some embodiments, the UTR comprises a wild-type UTR or a variant thereof, wherein the UTR variant comprises adding or removing one or more nucleotides at the end, including A, T, C or G. In some embodiments, the UTR variant also comprises codon optimization or modification performed in any manner. In some embodiments, the UTR variant also comprises a derivative sequence of any embodiment of the present invention, for example, based on the natural UTR sequence, the ATG point mutation is converted to GTG to inhibit the initiation of translation of the ATG inside the UTR.

[0287] carrier

[0288] The present disclosure also provides a kind of vector, it comprises the nucleic acid construct, RNA or polynucleotide described in any of the foregoing.Wherein the nucleic acid construct, RNA or polynucleotide may be present in a vector and / or may be a part of a vector, such as a plasmid, a cosmid, a YAC or a viral vector.The vector may be an expression vector, i.e. a vector for the expression of a nucleic acid construct, RNA or polynucleotide encoded polypeptide.The expression vector generally comprises at least one nucleic acid of the present disclosure, which is operably linked to one or more suitable expression control elements (such as promoters, terminators, etc.).It is common sense for those skilled in the art to select the elements and their sequences for expression in a specific host.The regulatory elements and other elements useful or necessary for the expression of the coded polypeptide of the present disclosure are, for example, promoters, terminators, selection markers, leader sequences, reporter genes, etc.

[0289] The nucleic acid constructs disclosed herein can be prepared or obtained by known means (eg, by automated DNA synthesis and / or recombinant DNA technology) based on the information of the nucleotide sequences disclosed herein, and / or can be isolated from suitable natural sources.

[0290] In some embodiments, the vector of the present disclosure further comprises a promoter, for example, the promoter is at the 5' end of the 5'UTR of the nucleic acid construct, for example, the promoter is T7 promoter, T7lac promoter, Tac promoter, Lac promoter, Trp promoter.

[0291] In some specific embodiments, the T7 promoter comprises or is the nucleotide sequence shown in SEQ ID NO: 17.

[0292] host cells

[0293] The present disclosure also provides a host cell comprising any of the aforementioned nucleic acid constructs, RNA, or polynucleotides. In some embodiments, the cell is capable of expressing one or more polypeptides encoded by the nucleic acid constructs, RNA, or polynucleotides of the present disclosure. In some embodiments, the host cell is a bacterial cell, a fungal cell, or a mammalian cell.

[0294] Examples of bacterial cells include cells of gram-negative bacterial strains (e.g., Escherichia coli strains, Proteus strains, and Pseudomonas strains) and gram-positive bacterial strains (e.g., Bacillus strains, Streptomyces strains, Staphylococcus strains, and Lactococcus strains).

[0295] Exemplary fungal cells include cells of species of the genera Trichoderma, Neurospora, and Aspergillus; or cells of species of the genera Saccharomyces (e.g., Saccharomyces cerevisiae), Schizosaccharomyces (e.g., Schizosaccharomyces pombe), Pichia (e.g., Pichia pastoris and Pichia methanolica), and Hansenula.

[0296] Examples of mammalian cells include HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, and the like.

[0297] However, the present disclosure may also be used with amphibian cells, insect cells, plant cells, and any other cells known in the art for expressing heterologous proteins.

[0298] Production or preparation method

[0299] The present disclosure provides a method for preparing the nucleic acid construct, RNA or polynucleotide of the present disclosure, and a method for preparing the polypeptide encoded therein.

[0300] Methods and reagents for preparing nucleic acid constructs, RNA or polynucleotides, and their encoded polypeptides, such as specific suitable vectors, transformation or transfection methods, selection markers, methods for inducing protein expression, culture conditions, etc. are known in the art. Similarly, protein isolation and purification techniques suitable for use in the methods of producing the encoded polypeptides of the present disclosure are well known to those skilled in the art.

[0301] In some embodiments, the method for preparing the nucleic acid construct, RNA or polynucleotide comprises culturing the aforementioned host cell and recovering the produced nucleic acid construct, RNA or polynucleotide from the culture. The nucleic acid construct, RNA or polynucleotide of the present disclosure, and the encoded polypeptide thereof can also be obtained by other production methods known in the art, such as chemical synthesis, including solid phase or liquid phase synthesis.

[0302] In some embodiments, the method for preparing an RNA molecule comprises: preparing a nucleic acid construct or vector, and then performing reverse transcription using the nucleic acid construct or vector to obtain an RNA molecule. In some specific embodiments, the method further comprises adding a 5' Cap to the 5' end of the RNA molecule.

[0303] vaccine

[0304] The present disclosure also provides a vaccine comprising the nucleic acid construct described in any of the foregoing, the RNA described in any of the foregoing, and / or the polynucleotide described in any of the foregoing. In some embodiments, the nucleic acid construct, RNA, or polynucleotide encodes one or more antigens of one or more viral strains. The vaccine provided herein can be a monovalent vaccine, a multivalent vaccine, or a combination vaccine.

[0305] Monovalent vaccines

[0306] The present disclosure provides a monovalent vaccine comprising an antigen encoding an organism. In some embodiments, the monovalent vaccine comprises an antigen encoding a viral strain.

[0307] Multivalent / combination vaccines

[0308] In some embodiments, the vaccine may include a nucleic acid construct, RNA, or polynucleotide molecule, or multiple nucleic acid constructs, RNA, or polynucleotide molecules, encoding two or more antigens of the same or different species. In some embodiments, the vaccine includes RNA or multiple RNAs encoding two or more antigens of the same or different viral strains. In some embodiments, the RNA may encode 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more viral antigens.

[0309] In some embodiments, in the above-mentioned monovalent vaccines and multivalent / combination vaccines, the antigen is a coronavirus antigen, such as SARS-CoV-2 (COVID-19), SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 or MERS-CoV. In some embodiments, the coronavirus antigen is a structural protein, such as a spike protein (S protein or Spike protein), an envelope protein (E protein), a membrane protein (M protein) and a nucleocapsid protein (N protein). In some embodiments, the structural protein is a spike protein, such as a SARS-COV-2 spike protein. In some embodiments, the SARS-COV-2 spike protein is selected from the spike protein of any virus strain such as SARS-COV-2 (e.g., wild-type SARS-COV-2 mRNA), SARS-COV-2 Alpha (B.1.1.7), SARS-COV-2 Beta (B.1.351), SARS-COV-2 Gamma (P.1), SARS-COV-2 Kappa (B.1.617.1), SARS-COV-2 Delta (B.1.617.2), SARS-COV-2 Omicron (B.1.1.529), and SARS-COV-2 Omicron (BA.4). In some embodiments, the SARS-COV-2 spike protein comprises or is an amino acid sequence as set forth in any one of SEQ ID NOs: 12, 14, 21, 23, 25, 80, 136, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto. In some embodiments, the DNA sequence encoding the SARS-COV-2 spike protein comprises or is a nucleotide sequence as set forth in any one of SEQ ID NOs: 13, 15, 20, 22, 24, 81, 97, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto. In some embodiments, the RNA sequence encoding the SARS-COV-2 spike protein comprises or is a nucleotide sequence as shown in SEQ ID NO: 54-55, 59-61, 82, 130, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0310] In some embodiments, the ORF encodes an influenza virus antigen. In some embodiments, the influenza virus is selected from influenza A virus or influenza B virus, illustratively, the influenza virus is influenza A virus H1N1, influenza A virus H3N2, influenza A virus H3N8, influenza A virus H2N2, influenza A virus H5N1, influenza A virus H9N2, influenza A virus H7N7, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), etc. In some embodiments, the influenza virus antigen is a structural protein of influenza virus, for example, hemagglutinin (HA), neuraminidase (NA), ion channel protein M2 (M2 ion channel), matrix protein M1 (matrix protein), nucleoprotein NP (nucleoprotein), etc. In some specific embodiments, the influenza virus antigen is an HA protein of an influenza virus, such as an HA protein of influenza A virus H1N1, influenza A virus H3N2, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), or influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013). In some embodiments, the HA protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 83-86, 98-101, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity thereto. In some embodiments, the DNA sequence encoding the HA protein comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 87-90, 93-97, 102-105, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto. In some embodiments, the RNA sequence encoding the HA protein comprises or is a nucleotide sequence as shown in any one of SEQ ID NOs: 126-129, 131-134, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity thereto.

[0311] In some embodiments, two or more different RNAs (e.g., mRNAs) can be formulated in the same lipid nanoparticle. In other embodiments, two or more different RNAs can be formulated in separate lipid nanoparticles, which can then be combined and administered as a single vaccine composition (e.g., including multiple RNAs encoding multiple antigens), or can be administered separately.

[0312] The present disclosure also provides multivalent / combination vaccines comprising RNA encoding one or more coronaviruses or one or more antigens from different organisms. That is, the vaccines of the present disclosure can be multivalent / combination vaccines targeting one or more antigens from the same strain / species, or one or more antigens from different strains / species.

[0313] Delivery system

[0314] The present disclosure also provides a delivery system comprising the nucleic acid construct described in any of the foregoing, or the RNA molecule described in any of the foregoing; wherein the delivery vehicle is a cationic lipid delivery particle. In some embodiments, wherein the particle is a nanoparticle. In some embodiments, the delivery vehicle is a nanolipid particle. The RNA molecules in the present disclosure can be delivered into cells and / or in vivo using any type of nanolipid particle in the art. For example, nanolipid particles can include but are not limited to lipid particles disclosed in WO2017075531, WO2018081480A1, WO2017049245A2, WO2017099823A1, WO2022245888A1, WO2022150717A1, CN101291653A, CN102119217A, WO2011000107A1, and CN107028886A, which are incorporated herein by reference in their entirety.

[0315] Pharmaceutical composition

[0316] The present disclosure also provides a pharmaceutical composition, comprising the nucleic acid construct described in any of the foregoing, the polynucleotide described in any of the foregoing, the vaccine described in any of the foregoing, the vector described in any of the foregoing, and / or the delivery vehicle described in any of the foregoing, and a pharmaceutically acceptable carrier, diluent or excipient. Specifically, the pharmaceutical composition is a solid preparation, an injection, an external preparation, a spray, a liquid preparation, or a compound preparation.

[0317] Products or kits

[0318] The present disclosure provides a product or kit comprising any of the aforementioned nucleic acid constructs, any of the aforementioned polynucleotides, any of the aforementioned vaccines, any of the aforementioned vectors, any of the aforementioned delivery vehicles, and / or any of the aforementioned pharmaceutical compositions. The kit can be used for related detection or diagnostic purposes.

[0319] Methods for treating and / or preventing diseases and pharmaceutical uses

[0320] The present disclosure also provides a method of administering to a subject in need thereof a therapeutically and / or prophylactically effective amount of a nucleic acid construct as described in any of the foregoing, a polynucleotide as described in any of the foregoing, a vaccine as described in any of the foregoing, a vector as described in any of the foregoing, a delivery vehicle as described in any of the foregoing, a pharmaceutical composition as described in any of the foregoing, and / or a product or kit as described in any of the foregoing, in the preparation of a medicament for treating and / or preventing a disease. In some embodiments, the disease comprises a viral infectious disease or a respiratory disease associated with a viral infection. In some embodiments, the virus is a coronavirus. In some embodiments, the coronavirus is a coronavirus that infects humans, such as SARS-CoV-2 (COVID-19), SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, or MERS-CoV. In some embodiments, the coronavirus is SARS-CoV-2. In some embodiments, the virus is an influenza virus. In some embodiments, the coronavirus is an influenza virus that infects humans, such as influenza A virus or influenza B virus. Illustratively, the influenza virus is influenza A virus H1N1, influenza A virus H3N2, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), etc. In some embodiments, the respiratory diseases associated with viral infection (e.g., respiratory diseases associated with SARS-CoV-2 infection) include simple infections such as fever, cough and sore throat, headache, rhinitis, etc., pneumonia, acute respiratory tract infection, severe acute respiratory infection (SARI), hypoxic respiratory failure and acute respiratory distress syndrome, sepsis and septic shock, severe acute respiratory syndrome (SARS), etc.

[0321] The present disclosure also provides a method for treating and / or preventing a disease, comprising administering to a subject in need thereof a therapeutically and / or preventive effective amount of a nucleic acid construct of any of the foregoing, a polynucleotide of any of the foregoing, a vaccine of any of the foregoing, a vector of any of the foregoing, a delivery vehicle of any of the foregoing, a pharmaceutical composition of any of the foregoing, and / or a product or kit of any of the foregoing. In some embodiments, the disease comprises a viral infectious disease or a respiratory disease associated with viral infection. In some embodiments, the virus is a coronavirus. In some embodiments, the coronavirus is a coronavirus that infects humans, such as SARS-CoV-2 (COVID-19), SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, or MERS-CoV. In some embodiments, the coronavirus is SARS-CoV-2. In some embodiments, the virus is an influenza virus. In some embodiments, the coronavirus is an influenza virus that infects humans, such as influenza A virus or influenza B virus. Illustratively, the influenza virus is influenza A virus H1N1, influenza A virus H3N2, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), etc. In some embodiments, the respiratory diseases associated with viral infection (e.g., respiratory diseases associated with SARS-CoV-2 infection) include simple infections such as fever, cough and sore throat, headache, rhinitis, etc., pneumonia, acute respiratory tract infection, severe acute respiratory infection (SARI), hypoxic respiratory failure and acute respiratory distress syndrome, sepsis and septic shock, severe acute respiratory syndrome (SARS), etc.

[0322] The present disclosure also provides a method comprising administering to a subject in need thereof an effective amount of the nucleic acid construct of any of the foregoing, the polynucleotide of any of the foregoing, the vaccine of any of the foregoing, the vector of any of the foregoing, the delivery vehicle of any of the foregoing, the pharmaceutical composition of any of the foregoing, and / or the product or kit of any of the foregoing, which can induce a neutralizing antibody response and / or a T cell immune response in the subject, such as a neutralizing antibody response to a viral antigen, such as a CD4+ and / or CD8+ T cell immune response to a viral antigen. Wherein the antigen-antibody titer of the subject is increased after vaccination relative to the antigen-antibody titer of the subject vaccinated with a prophylactic effective dose of a traditional vaccine for the antigen. In some embodiments, the virus is a coronavirus. In some embodiments, the coronavirus is a coronavirus that infects humans, such as SARS-CoV-2 (COVID-19), SARS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 or MERS-CoV. In some embodiments, the coronavirus is SARS-CoV-2. In some embodiments, the virus is an influenza virus. In some embodiments, the coronavirus is an influenza virus that infects humans, such as influenza A virus or influenza B virus. Exemplary influenza viruses are influenza A virus H1N1, influenza A virus H3N2, influenza B virus / Victoria (e.g., Influenza B / Washington / 02 / 2019), influenza B virus / Yamagata (e.g., Influenza B / Phuket / 3073 / 2013), and the like.

[0323] In some embodiments, the subject is immune. In some embodiments, the subject has a lung disease. In some embodiments, the subject is 5 years of age or younger, or 65 years of age or older.

[0324] In some embodiments, the method comprises administering to the subject at least one, two, three, four or more doses of any of the aforementioned nucleic acid constructs, any of the aforementioned polynucleotides, any of the aforementioned vaccines, any of the aforementioned vectors, any of the aforementioned delivery vehicles, any of the aforementioned pharmaceutical compositions, or any of the aforementioned products or kits.

[0325] In some embodiments, 1-72 hours after administration of the nucleic acid construct of any of the foregoing, the polynucleotide of any of the foregoing, the vaccine of any of the foregoing, the vector of any of the foregoing, the delivery vehicle of any of the foregoing, the pharmaceutical composition of any of the foregoing, or the product or kit of any of the foregoing, a detectable level of viral antigen (such as a coronavirus antigen) is produced in the serum of the subject. In some embodiments, a neutralizing antibody titer of at least 100NU / mL, 200NU / mL, 300NU / mL, 400NU / mL, 500NU / mL, 600NU / mL, 700NU / mL, 800NU / mL, 900NU / mL or 1000NU / mL is produced in the serum of the subject 1-72 hours after administration.

[0326] In some embodiments, the antibody titer produced in the subject is increased by at least 1 log relative to the control. For example, the antibody titer produced in the subject can be increased by at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 log relative to the control.

[0327] In some embodiments, the antibody titer produced in the subject is increased by at least 2 times relative to the control. For example, the antibody titer produced by the subject is increased by at least 3, 4, 5, 6, 7, 8, 9 or 10 times relative to the control. In some embodiments, the geometric mean is the product of n numbers raised to the power of n, and is generally used to describe proportional growth. In some embodiments, the geometric mean is used to characterize the antibody titer produced in the subject. In some embodiments, the control can be an unvaccinated subject, or a subject administered a live attenuated virus vaccine, an inactivated virus vaccine or a protein subunit vaccine.

[0328] Vaccine efficacy

[0329] In some embodiments, the antigen-specific immune response is characterized by measuring the antibody titer against (coronavirus) antigens produced in the subject after receiving the administration of the aforementioned embodiment. Antibody titer is a measurement of the amount of antibodies in the subject, for example, antibodies specific to a specific antigen or epitope of an antigen. Antibody titer is typically expressed as the reciprocal of the maximum dilution that provides a positive result. Enzyme-linked immunosorbent assay (ELISA) is a common assay for determining antibody titers.

[0330] In some embodiments, antibody titers are used to assess whether a subject has been infected or to determine whether immunization is needed. In some embodiments, antibody titers are used to determine the strength of an autoimmune response, determine whether a booster immunization is needed, determine whether a previous vaccine was effective, and identify any recent or prior infection. According to the present disclosure, antibody titers can be used to determine the strength of an immune response induced in a subject by an immune composition (e.g., an RNA vaccine).

[0331] In some embodiments, the antibody titer against a (coronavirus) antigen produced in a subject is increased by at least 1 log relative to a control. For example, the antibody titer produced in a subject can be increased by at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 log relative to a control.

[0332] In some embodiments, the antibody titer produced in the subject is increased by at least 2-fold relative to the control. For example, the antibody titer produced in the subject is increased by at least 3, 4, 5, 6, 7, 8, 9 or 10-fold relative to the control.

[0333] In some embodiments, the antigen-specific immune response is measured as the ratio of serum neutralizing antibody titers to the geometric mean titer (GMT) of the coronavirus, referred to as the geometric mean ratio (GMR). The geometric mean titer (GMT) is the average antibody titer of a group of subjects, calculated by multiplying all values ​​and taking the nth root, where n is the number of subjects with available data.

[0334] In some embodiments, the control can be an unvaccinated subject, or a subject administered a live attenuated virus vaccine, an inactivated virus vaccine, or a protein subunit vaccine.

[0335] In some embodiments, vaccine efficacy can be assessed using standard analytical methods (e.g., see Weinberg et al., J Infect Dis. 2010 Jun 1; 201(11): 1607-10). For example, vaccine efficacy can be measured by a double-blind, randomized, controlled clinical trial. Vaccine efficacy can be expressed as the proportional reduction in the incidence of disease (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease in the vaccinated group using the following formula.

[0336] Efficacy = (ARU - ARV) / ARU x 100; and

[0337] Efficacy = (1-RR) x 100

[0338] In other embodiments, standard analyses can be used to assess the effectiveness of a vaccine (e.g., see Weinberg et al., J Infect Dis. 2010 Jun 1; 201(11): 1607-10). Vaccine effectiveness is an assessment of how well a vaccine (which may have been shown to have high vaccine efficacy) reduces disease in a population. This measure assesses the net balance of favorable and unfavorable effects of a vaccination program under natural conditions rather than in controlled clinical trials, rather than just the vaccine itself. Vaccine effectiveness is proportional to vaccine efficacy, but is also affected by the degree of immunity in the target group in the population, as well as other non-vaccine-related factors such as hospitalizations, outpatient visits, or costs. For example, a retrospective case-control analysis can be used, that is, comparing vaccination rates in a group of infected cases and an appropriate control group. Vaccine effectiveness can be expressed as a rate difference, using the odds (OR) of still getting infected after vaccination.

[0339] Effectiveness = (1-OR) × 100. BRIEF DESCRIPTION OF THE DRAWINGS

[0340] Figure 1: Schematic diagram of the plasmid template containing the T7 promoter, 5'UTR, 3'UTR, polyA tail and CDS sequence of the exogenous gene.

[0341] Figure 2: Electrophoresis of an mRNA microarray using a linearized plasmid as a template for in vitro transcription. L represents an RNA molecular weight marker (RNA Ladder) and 1 represents the purified mRNA sample.

[0342] Figure 3: ELISA analysis of the differences in SAS-Cov-2B.1.351 spike protein expression levels resulting from different 5'UTR and 3'UTR combinations. The abbreviations for 5'UTR and 3'UTR are shown in Table 3.

[0343] Figure 4: ELISA detection of differences in SAS-Cov-2B.1.1.7 spike protein expression levels resulting from different 5'UTR and 3'UTR combinations. The abbreviations for 5'UTR and 3'UTR are shown in Table 3.

[0344] Figure 5: Schematic diagram of 5'UTR I point mutation to 5'UTR I'.

[0345] Figure 6: Western blot analysis of the difference in SAS-Cov-2B.1.617.2 spike protein expression levels before and after the 5'UTR I point mutation. Samples 1 and 3 used 5'UTR I, while samples 2 and 4 used 5'UTR I'; the mRNA synthesis templates for samples 1 and 2 were derived from plasmid minipreps, while those for samples 3 and 4 were derived from plasmid maxipres; sample 5 was a control supernatant from untransfected cells; M is a molecular weight marker. Figure 6A is a Western blot image, and Figure 6B is a sample ratio image after quantification of the Western blot image.

[0346] Figure 7: Western blot analysis of the effect of 5'UTR I' on the expression levels of different heterologous genes. Figure 7A is a Western blot analysis, and Figure 7B is a graph showing the relative values ​​of samples after quantification of the Western blot analysis.

[0347] FIG8 : Luciferase expression mediated by 5′UTR I′-3′UTR B and 5′UTR I-3′UTR B compared to the BNT162b 2UTR combination.

[0348] FIG9 shows the results of regulation of luciferase expression by 5'UTR I' truncation and 5'UTR I' mutant.

[0349] Figure 10: Differences in HA mRNA expression levels under the regulation of 5'UTR I' and control 5'UTR. DETAILED DESCRIPTION

[0350] the term

[0351] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise explicitly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present disclosure belongs.

[0352] The official classification name of "2019 Novel Coronavirus (2019-nCoV)" is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

[0353] The official name of the disease caused by the 2019 novel coronavirus (2019-nCoV) is COVID-19.

[0354] "Nucleic acid" or "nucleotide" includes RNA, DNA and cDNA molecules. It should be understood that due to the degeneracy of the genetic code, a large number of nucleotide sequences encoding a given protein can be produced. The term nucleic acid can be used interchangeably with the term "polynucleotide". "Oligonucleotide" is a short-chain nucleic acid molecule. "Primer" is an oligonucleotide, whether naturally occurring in a purified restriction enzyme digestion or synthetically produced, which can serve as a synthesis starting point when placed under conditions that induce the synthesis of primer extension products complementary to the nucleic acid chain (i.e., in the presence of nucleotides and an inducing agent such as DNA polymerase, and at a suitable temperature and pH). In order to maximize amplification efficiency, the primer is preferably single-stranded, but can alternatively be double-stranded. If double-stranded, then before being used to prepare an extension product, the primer is first treated to separate its chain. Preferably, the primer is a deoxyribonucleotide. The primer must be long enough to initiate the synthesis of the extension product in the presence of an inducing agent. The exact length of the primer will depend on many factors, including temperature, primer source and the method used.

[0355] "Vector" or "expression vector" refers to a replicon, such as a plasmid, bacmid, phage, virus, virion or cosmid, to which another DNA segment, i.e., an "insert," can be attached to achieve replication of the attached segment in a cell. A vector can be a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral in origin and / or final form, such as the pUC57 DNA vector used herein. The term "vector" encompasses any genetic element that is capable of replication and can transfer a gene sequence to a cell when combined with appropriate control elements. In some embodiments, a vector can be an expression vector or a recombinant vector.

[0356] "Promoter" refers to any nucleic acid sequence that regulates the expression of another nucleic acid sequence, which may be a heterologous target gene encoding a protein or RNA, by driving the transcription of that nucleic acid sequence. Promoters can be constitutive, inducible, repressible, tissue-specific, or any combination thereof. A promoter is a control region of a nucleic acid sequence where the initiation and transcription rate of the remainder of the nucleic acid sequence are controlled.

[0357] "Gene" refers to a DNA segment involved in producing a polypeptide chain, and may or may not include preceding and following coding regions, for example, 5' untranslated (5'UTR) or "leader" sequence and 3'UTR or "untranscribed trailer" sequence, as well as intervening sequences (introns) between respective coding segments (exons).

[0358] "Recombinant" means that the polynucleotide is the product of various combinations of cloning, restriction or ligation steps, and other steps that result in a construct that is different and / or distinct from a naturally occurring polynucleotide.

[0359] "Introduced," in the context of inserting a nucleic acid sequence into a cell, means "transfection," "transformation," or "transduction" and includes the incorporation of a reference nucleic acid sequence into a eukaryotic or prokaryotic cell, where the nucleic acid sequence can be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), transferred to autonomous replication, or transiently expressed (e.g., transfected mRNA).

[0360] "Nucleic acid construct" refers to a single-stranded or double-stranded nucleic acid molecule, such as a DNA fragment, which has been modified or synthesized to contain a nucleic acid segment in a manner not naturally present, said nucleic acid molecule comprising one or more control sequences or regulatory elements. In the context of the present disclosure, a nucleic acid construct contains a recombinant nucleotide sequence that essentially consists of, optionally, one, two, three or more isolated nucleotide sequences: including a 5'UTR, an open reading frame (ORF), and a 3'UTR. In embodiments involving constructs comprising two or more sequences, the sequences are operably linked to each other in the construct.

[0361] "Derived sequence" refers to a nucleotide sequence that is highly homologous to the UTR sequence disclosed herein (e.g., at least 80%, 85%, 88%, 90%, 93%, 95%, 96%, 97%, 98%, 99%, 100% identical to the UTR sequence disclosed herein) and still retains the same or similar functional activity as the UTR sequence disclosed herein. In some embodiments, the derivative sequence is a nucleotide sequence obtained by substitution, deletion or addition of one or more nucleotides on the basis of the natural UTR sequence. In some embodiments, the derivative sequence is a nucleotide sequence obtained by truncation on the basis of the natural UTR sequence. In some embodiments, the derivative sequence is a point mutation of ATG to GTG, CTG or TTG on the basis of the natural UTR sequence, which is used to inhibit the initiation of translation of ATG inside the UTR.

[0362] "Operably linked" is defined herein as a structure in which the control sequences, i.e., promoter sequence and / or 5'UTR sequence, are appropriately placed at positions relative to the coding DNA sequence such that the control sequences direct the transcription of the coding sequence and translation of mRNA into the polypeptide sequence encoded by the coding DNA.

[0363] "Open reading frame" abbreviated as "ORF" refers to a segment or region of an mRNA molecule that encodes a polypeptide. An ORF consists of consecutive, non-overlapping in-frame codons, starting with a start codon and ending with a stop codon, and is translated by the ribosome.

[0364] "Endogenous" refers to any substance that originates from or is produced within an organism, cell, tissue, or system.

[0365] "Exogenous" refers to any substance introduced into or generated from outside an organism, cell, tissue, or system.

[0366] "Sequence identity" or "sequence identity" refers to the sequence identity between genes or proteins at the nucleotide or amino acid level, respectively. "Sequence identity" or "sequence identity" is a measure of identity between proteins at the amino acid level and a measure of identity between nucleic acids at the nucleotide level. Protein sequence identity can be determined by comparing the amino acid sequence at a given position in each sequence when the sequences are aligned. Similarly, nucleic acid sequence identity can be determined by comparing the nucleotide sequence at a given position in each sequence when the sequences are aligned. Methods for aligning sequences for comparison are well known in the art, and such methods include GAP, BESTFIT, BLAST, FASTA, and TFASTA. The BLAST algorithm calculates sequence identity percentages and performs statistical analysis on the similarity between two sequences. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information (NCBI) website.

[0367] "Homology" or "homology" is defined as the percentage of nucleotide residues that are consistent with the nucleotide residues in the corresponding sequence on the target chromosome after aligning the sequences and, if necessary, introducing spaces to achieve maximum sequence identity. Comparisons for determining nucleotide sequence homology percentages can be achieved in various ways within the skill of the art, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, ClustalW2 or Megalign (DNASTAR) software. In some specific embodiments, the present disclosure calculates sequence homology percentages based on BLAST. Those skilled in the art can determine suitable parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequences. In some embodiments, a sequence is considered "homologous" when, for example, a nucleic acid sequence (e.g., a DNA sequence) of a homology arm is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to a corresponding native or unedited nucleic acid sequence (e.g., genomic sequence) of a host cell.

[0368] A "substitution" is defined as a change in an amino acid or nucleotide sequence resulting from the replacement of one or more amino acids or nucleotides with a different amino acid or nucleotide, respectively, compared to the amino acid sequence or nucleotide sequence of a reference polypeptide. If a substitution is conservative, the amino acid substituted into the polypeptide has similar structural or chemical properties (e.g., charge, polarity, hydrophobicity, etc.) to the amino acid it replaces. In some embodiments, polypeptide variants may have "non-conservative" changes, in which the substituted amino acids differ in structure and / or chemical properties.

[0369] A "deletion" is defined as a change in an amino acid or nucleotide sequence that results in the absence of one or more amino acid or nucleotide residues, respectively, compared to the amino acid sequence or nucleotide sequence of a reference polypeptide. In the case of a polypeptide or polynucleotide sequence, a deletion may involve the absence of 2, 5, 10, up to 20, up to 30, or up to 50 or more amino acid or nucleotide residues, taking into account the length of the modified polypeptide or polynucleotide sequence.

[0370] "Insertion" or "addition" refers to a change in an amino acid or nucleotide sequence that results in the addition of one or more amino acid or nucleotide residues, respectively, compared to the amino acid sequence or nucleotide sequence of a reference polypeptide. "Insertion" generally refers to the addition of one or more amino acid residues within the amino acid sequence of a polypeptide (or nucleotide residues within a polynucleotide), while "addition" can be an insertion or refer to an amino acid residue added to the N- or C-terminus of a polypeptide (or a nucleotide residue added to the 5' or 3' terminus of a polynucleotide). In the case of a polypeptide or polynucleotide sequence, an insertion or addition can be up to 10, up to 20, up to 30, up to 50 or more amino acids (or nucleotide residues).

[0371] "Codon optimization" refers to the replacement of a generally rare codon in a highly expressed gene of a given species with a generally common codon in the highly expressed gene of such species in a target sequence, and the codons before and after the replacement encode the same amino acid. Various species show specific preferences for certain codons of specific amino acids. Codon preference (the difference in codon usage between organisms) is generally related to the translation efficiency of messenger RNA (mRNA), and it is then believed that the messenger RNA is particularly dependent on the characteristics of the codons translated and the availability of specific transfer RNA (tRNA) molecules. The advantage of the selected tRNA in the cell is generally a reflection of the most commonly used codons in peptide synthesis. Therefore, based on codon optimization, genes can be modified for the optimal gene expression in a given organism. Therefore, the selection of optimal codons depends on the codon usage preference of the host genome.

[0372] "Antigen-antibody" refers to a serum antibody that specifically binds to an antigen.

[0373] "Cell" or "host cell" includes any cell type that is susceptible to transformation, transfection, transduction, etc. by the nucleic acid constructs or vectors of the present disclosure. As non-limiting examples, the host cell can be an isolated primary cell, a pluripotent stem cell, a CD34+ cell, an induced pluripotent stem cell, or any of a number of immortalized cell lines (e.g., HepG2 cells). Alternatively, the host cell can be an in situ or in vivo cell in a tissue, organ, or organism.

[0374] "Treatment" means administering an internal or external therapeutic agent, such as a composition comprising any of the nucleic acid constructs disclosed herein, to a patient having one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, a therapeutic agent is administered to a patient or population treated in an amount effective to alleviate one or more symptoms of a disease, to induce regression of such symptoms or to inhibit the development of such symptoms to any clinically measurable degree. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") can vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether a symptom of a disease has been alleviated can be assessed by any clinical test commonly used by physicians or other health care professionals to assess the severity or progression of the symptom.

[0375] An "effective amount" or "pharmaceutically effective amount" encompasses an amount sufficient to ameliorate or prevent the symptoms or conditions of a medical disease. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects. In some embodiments, an "effective amount" is an effective dose of RNA that can produce an antigen-specific immune response.

[0376] "Prophylactic effective dose" refers to an effective dose for preventing viral infection at a clinically acceptable level. In some embodiments, the effective dose is the dose listed in the vaccine package insert. Traditional vaccines, as used herein, refer to vaccines other than the mRNA vaccines disclosed herein. For example, traditional vaccines include but are not limited to live microbial vaccines, killed microbial vaccines, subunit vaccines, protein antigen vaccines, DNA vaccines, virus-like particle (VLP) vaccines, and the like. In an exemplary embodiment, a traditional vaccine is a vaccine that has been approved by a regulatory authority and / or registered by a national drug regulatory agency, such as the China Food and Drug Administration.

[0377] "Pharmaceutically acceptable" means that these therapeutic agents, materials, compositions and / or dosage forms are, within the scope of sound medical judgment, suitable for use in contact with patient tissues without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio, and effective for the intended use.

[0378] "Monovalent vaccine" refers to a vaccine preparation for immunization made from one serotype antigen of a pathogen. For example, a vaccine containing only one antigen of a SARS-CoV-2 strain disclosed herein is a monovalent vaccine.

[0379] A "multivalent vaccine" is a vaccine product used for immunization that is made from antigens from multiple serotypes of the same pathogen. For example, a vaccine containing antigens from one SARS-CoV-2 variant mixed with one or more antigens from other SARS-CoV-2 variants of different subtypes is a multivalent vaccine.

[0380] "Combination vaccine" refers to a vaccine product for immunization made from multiple serotype antigens of different pathogens. For example, a vaccine containing the SARS-CoV-2 strain antigens disclosed herein mixed with several pathogenic microorganisms that can prevent and / or treat other viruses is a combination vaccine. Combination vaccines are generally prepared by the same production method to prepare monovalent vaccines, which are then mixed in the same injection for immunization; or, antigens of several pathogenic microorganisms are mixed and then prepared into a vaccine product. In some specific embodiments, the present disclosure first mixes pathogenic microorganism antigens and then prepares them into a vaccine product. Combined, multivalent vaccines are the future development trend, and their advantages are: (1) saving the cost of vaccination; (2) saving the cost of packaging, logistics and assembly of multiple individual vaccines; (3) reducing harm to vaccine recipients, especially infants; (4) increasing vaccination coverage; (5) saving vaccination time; (6) reducing vaccine storage space, etc. Combined or multivalent vaccines can save direct and indirect costs, including multiple medical visits and missed vaccinations. For example, the currently commonly used multivalent combination vaccines include pneumococcal, meningococcal, poliovirus, rotavirus, influenza, HPV and other vaccines.

[0381] An "immune response" to a vaccine of the present disclosure refers to a subject's production of a humoral and / or cellular immune response to the viral protein(s) (eg, coronavirus) present in the vaccine. For purposes of this disclosure, a "humoral" immune response refers to an immune response mediated by antibody molecules, including, for example, secretory IgA or IgG molecules, while a "cellular" immune response is an immune response mediated by T lymphocytes (e.g., CD4+ helper and / or CD8+ T cells (e.g., CTLs) and / or other white blood cells. An important aspect of cellular immunity involves the antigen-specific response of cytolytic T cells (CTLs). CTLs are specific for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the cell surface, and CTLs help induce and promote the destruction of intracellular microorganisms or lysis of cells infected with these microorganisms. Another aspect of cellular immunity involves the antigen-specific response of helper T cells, which help stimulate the function and focus the activity of nonspecific effector cells on cells that present peptide antigens in association with MHC molecules. Cellular immune responses also result in the production of cytokines, chemokines, and other such molecules by activated T cells and / or other white blood cells.

[0382] Example

[0383] The present disclosure is further described below with reference to the following examples, but these examples are not intended to limit the scope of this disclosure. Experimental methods in the examples herein where specific conditions are not specified generally follow conventional conditions, such as those found in cell culture manuals and molecular cloning manuals, or according to the conditions recommended by the raw material or product manufacturer. Reagents where the specific source is not specified are commercially available.

[0384] The following routine experimental procedures 1) to 4) are exemplified:

[0385] 1) mRNA production

[0386] To generate in vitro transcribed mRNA, the plasmid was linearized downstream of the polyadenylation tail using BspQ 1 (Vazyme, DD4302-PC, China) and purified using a PCR purification kit (QIAGEN, 28106, Germany). The purified linearized plasmid was used as a template for in vitro transcription using a T7 in vitro transcription kit (Invitrogen, AM1333, USA). The mRNA synthesized by in vitro transcription was purified using MEGAclear TM Kit (Invitrogen, AM1908, USA) was used to purify mRNA of relatively high purity for subsequent in vitro cell transfection experiments.

[0387] 2) Chip electrophoresis

[0388] To verify the integrity and purity of in vitro transcribed mRNA, we analyzed it using a chip electrophoresis instrument (Agilent 2100, USA) and the RNA 6000 Nano Kit (Agilent, 5067-1511, USA). The experimental method was as follows: the mRNA to be tested was denatured (incubated at 70°C for 2 minutes and immediately placed on ice). The treated samples were then spotted onto the corresponding wells of the chip. The machine was then run and the analysis results were generated.

[0389] 3) Cell culture

[0390] Materials: FBS (Gibco), DMEM medium (Gibco), Opti-MEM (Gibco), PBS (Gibco), trypsin-EDTA (Gibco), double antibody (Pen / Strep, Gibco) and Lipofectamine TM 2000 (Invitrogen, 52887).

[0391] Human embryonic kidney cells (293T, ATCC) were grown in DMEM medium supplemented with 10% FBS and 1% double antibody in a humidified atmosphere of 5% CO 2 .

[0392] 4) In vitro transfection

[0393] 8 hours before transfection, 8×10 5 Cells were seeded in 12-well cell culture plates using the commercial transfection reagent Lipofectamine. TM 2000 per 1 μg mRNA and 2.5 μL Lipofectamine TM The cell transfection was performed at a ratio of 2000, and the mRNA transfection dose for each well was 2 μg. The experimental method is as follows: Lipofectamine TM 2000 and mRNA were diluted in Opti-MEM medium to a final total volume of 100 μL, and then Lipofectamine TM2000 solution and mRNA solution were mixed and incubated at room temperature for 10-15 minutes to form liposome complexes containing mRNA. After removing the DMEM medium from the cell culture well plate, the liposome complexes containing different mRNAs were added to the corresponding well plates, and then 400 μL of Opti-MEM medium containing 10% FBS was added to each well, and the cells were cultured at 37°C (5% CO2 level) for 4-6 hours. Thereafter, the transfection medium was removed, and 1 mL of DMEM medium supplemented with 10% FBS and 1% double antibody was added to each cell culture well plate, and the cells were cultured at 37°C (5% CO2 level) for 48 hours. At the same time, some cells were transfected with Lipofectamine 50% dapoxetine containing no mRNA in the same manner as described above. TM 2000 solution was used as a negative control.

[0394] The target gene sequences used in this disclosure are summarized here, see Table 1.

[0395] Table 1. Target gene sequence information of the present disclosure

[0396] The amino acid mutation KV to PP in the SARS-COV-2 spike protein can change the spike protein from an unstable prefusion conformation to a stable postfusion conformation (Structure-based design of prefusion-stabilized SARS-CoV-2 spikes, Science, VOL.369, NO.6510), making the spike protein conformationally stable, which is beneficial for vaccine design and production using the spike protein as an immunogen.

[0397] Example 1. Screening and preparation of 5'UTR sequences

[0398] 1. UTR screening

[0399] In order to obtain a regulatory element capable of highly expressing a target protein in dendritic cells (DC), this example obtained a novel UTR structure through four-level screening.

[0400] Methods included: 1. Establishing a library of highly expressed protein genes, including genes with high protein expression in monocytes, genes with higher protein expression in DCs compared to monocytes, genes with higher protein levels, and genes with UTRs that were tested to increase protein expression, resulting in 2,140 genes. 2. Establishing a UTR library: After downloading all sequences from the library of highly expressed protein genes from the Genbank database (https: / / www.ncbi.nlm.nih.gov / genbank / ), the completeness of the sequences was analyzed, followed by analysis using methods such as duplicate merging and CDS (coding sequence) extraction to obtain UTR data, resulting in 940 UTRs. Third: Establish a UTR selection library, analyze the UTR library, and screen for UTR sequences with appropriate sequence length and free energy. The 5'UTR sequence length is between 40 and 70, and the 3'UTR length is between 100 and 150 or 300 and 400. Free energy prediction is performed on each sequence, selecting sequences with high 5'UTR free energy and low 3'UTR free energy. 64 UTRs were obtained from this selected library. Fourth: Final candidate sequences were determined. The screening strategy was 5'UTR free energy above -10 and 3'UTR free energy very low. Ultimately, 20 5'UTRs and 3'UTRs were selected for screening and in-cell verification.

[0401] Based on the above, we believe that the 5'UTR sequence derived from human Rho GTPase activating protein 15 (ARHGAP15) (designated 5'UTR I, DNA sequence shown in SEQ ID NO: 1, RNA sequence shown in SEQ ID NO: 45) has the potential to efficiently express the target protein in human cells (especially DCs).

[0402] 2. Preparation of UTR

[0403] This example illustrates the preparation of mRNA containing 5'UTR 1. First, a sequence containing the 5'UTR, 3'UTR, polyA tail, and CDS of the exogenous target gene was artificially synthesized and inserted into the pUC57 vector to create a template vector, a schematic of which is shown in Figure 1. Sequencing confirmed that the target gene sequence inserted into the vector was correct.

[0404] As shown in the pUC57Delta13 vector in Figure 1, the 5'UTR is SEQ ID NO: 1; the 3'UTR is the human hemoglobin β subunit (HBB) 3'UTR sequence (SEQ ID NO: 7, named 3'UTR B); the CDS sequence is a codon-optimized base sequence encoding the B.1.617.2 (Delta) spike protein (SEQ ID NO: 13); the polyA tail is a polyadenylic acid sequence (the DNA sequence is shown in SEQ ID NO: 16, and the RNA sequence is shown in SEQ ID NO: 56); and the T7 promoter (SEQ ID NO: 17).

[0405] In order to produce in vitro transcribed mRNA, the plasmid was linearized downstream of the polyadenylic acid tail using BspQ I (Vazyme, DD4302-PC, China) and purified using a PCR purification kit (QIAGEN, 28106, Germany). Using the purified linearized plasmid as a template, in vitro transcription and mRNA synthesis were performed according to the following process. A 100 μL mRNA reaction system was synthesized, and the reaction system is shown in Table 2. In the reaction system, the linearized template was 2 μg, and 100 μL was added with nuclease-free water. The reaction was incubated at 37°C for 4 hours and digested with DNase I for 30 minutes. After testing, the synthesized mRNA contained little byproduct dsRNA and had an excellent yield. The capping process was achieved during in vitro transcription synthesis using a chemical capping method, and the cap structure was m7G(5')ppp(5')(2'OMeA)pG·NH4 (Hongene, ON-134). After MEGAclear TM Kit (Invitrogen, AM1908, USA) was used to purify mRNA of relatively high purity for subsequent in vitro cell transfection experiments.

[0406] Table 2. mRNA reaction system

[0407] After multiple rounds of screening and functional verification, the present invention obtained a 5'UTR I with the potential to efficiently express the target protein, whose sequence is SEQ ID NO: 1; and the construction containing 5'UTR I can efficiently transcribe the corresponding mRNA, which is consistent with the theoretical size as identified by chip electrophoresis (see Figure 2).

[0408] Example 2: Screening for different 5'UTR and 3'UTR combinations for efficient expression of heterologous proteins

[0409] In this example, combinations of different 5'UTRs and different 3'UTRs were screened to obtain a UTR combination that can efficiently express the target gene.

[0410] The method is as follows: artificially synthesize a plasmid containing different UTR combinations of the CDS of the same target gene. Construct a basic plasmid using the method of Example 1, reconstruct and replace the target gene CDS sequence by artificial synthesis and HindIII / XhoI digestion, linearize the reconstructed plasmid and synthesize and purify mRNA according to the method of Example 1. TM 2000 mRNA was transfected into 293T cells. After 48 hours, the 293T supernatant was collected and subjected to Western blotting and ELISA tests to detect the level of spike protein in the secreted cell supernatant.

[0411] The target genes used are: the gene encoding the novel coronavirus B.1.351 spike protein (CDS as shown in SEQ ID NO: 20), or the gene encoding the novel coronavirus B.1.1.7 spike protein (CDS as shown in SEQ ID NO: 22). The information of the different 5'UTRs and 3'UTRs used and their combinations are shown in Tables 3 and 4.

[0412] Western blotting: To determine the in vitro expression level of each construct's mRNA, the cell supernatant was collected from the wells after transfection and analyzed by polyacrylamide gel electrophoresis, transfer to a membrane, incubation with primary and secondary antibodies, and development. The primary antibody used was an antibody against the SARS-CoV-2 (2019-nCoV) spike protein RBD (Sino Biology, 40592-T62), and the secondary antibody was an HRP-linked anti-rabbit IgG (Transgene, HS101).

[0413] ELISA method: After transfection, the corresponding cell supernatant was collected and diluted at a ratio of 1:50 to 1:100. The expression level of each constructed mRNA in vitro was detected using an ELISA kit (SARS-CoV-2 (2019-nCoV) Spike Detection ELISA Kit, KIT40591, Sino Biology). The absorbance value at 450 nm was read and the concentration of the relevant antigen was calculated.

[0414] Table 3. Origins and sequences of 5'UTR and 3'UTR

[0415] Table 4. Different 5'UTR and 3'UTR combinations

[0416] In Table 4, A, G, I and J of the 5'UTR are shown in SEQ ID NOs: 4, 3, 1 and 5, respectively; B, E, D and F of the 3'UTR are shown in SEQ ID NOs: 7, 9, 10 and 8, respectively.

[0417] The effects of different 5'UTR and 3'UTR combinations on the expression of SARS-CoV-2 B.1.351 spike protein and SARS-CoV-2 B.1.1.7 spike protein are shown in Figure 3 and Table 5, and Figure 4 and Table 6, respectively.

[0418] Table 5. Regulation results of different UTR combinations on B.1.351 spike protein expression (ELISA test) (The sample numbering rule is, for example, #1:AB represents sample #1, which is the UTR combination of AB)

[0419] Table 6. Regulation results of different UTR combinations on B.1.1.7 spike protein expression (ELISA test) (The sample numbering rule is, for example, UK-#11:IE represents sample UK-#11, which is the UTR combination of IE)

[0420] According to Figure 3 and Table 5, the expression levels of the B.1.351 spike protein mediated by different UTR combinations are compared as follows: IB>AB>GB, IB>IE. For 5'UTR, I is better than A and G; for the relevant combinations of I, IB is better than IE. According to Figure 4 and Table 6, the expression levels of the B.1.1.7 spike protein mediated by different UTR combinations are compared as follows: IF>IB>ID>IE. Based on the analysis of the expression levels of the B.1.351 spike and B.1.1.7 spike proteins, the IB UTR combination has a more significant advantage and can mediate the efficient expression of the target gene. In addition, the IF combination also shows the advantage of high-level expression of the target gene.

[0421] Furthermore, we prepared B.1.617.2 spike mRNA under the regulation of IB or IF, and performed cell transfection and ELISA detection. The results of the spike protein expression test are shown in Table 7.

[0422] Table 7. B.1.617.2 spike protein expression regulated by IB and IF UTR (ELISA test)

[0423] Unlike the IB combination, where the 5'UTR and 3'UTR are derived from different genes, the IF combination's 5'UTR and 3'UTR are derived from the same gene, ARHGAP15. The results in Table 7 show that the IB (SEQ ID NO: 1 and SEQ ID NO: 7) and IF (SEQ ID NO: 1 and SEQ ID NO: 8) combinations regulate target gene expression to comparable levels, further demonstrating the versatility of 5'UTR I, which can be combined with different 3'UTRs to mediate efficient expression of target genes (e.g., genes encoding spike proteins).

[0424] Example 3: Sequence modification and preliminary functional verification of 5'UTR I

[0425] 1) Bioinformatics analysis and mutation design

[0426] 5'UTR I (SEQ ID NO: 1) is a naturally occurring human Rho GTPase activating protein family promoter. The experimental data of Examples 1-2 support that 5'UTR I assists in the efficient expression of the new crown spike protein, but 5'UTR I contains an ATG inside, which may express a short peptide of 27aa, affecting the normal expression of the target gene protein. In order to avoid the phenomenon that the ribosome initiates translation from the ATG inside the UTR, increase the probability of translation from the ATG in the CDS region, and increase the expression amount, the present disclosure performed a point mutation (A→G) to obtain a mutant 5'UTR I' (the DNA sequence is shown in SEQ ID NO: 2, and the RNA sequence is shown in SEQ ID NO: 46). The mutation position is shown in Figure 5.

[0427] 2) Point mutation of 5'UTR I to 5'UTR I' can effectively increase the expression of the target gene

[0428] The method of Example 1 was used to prepare plasmids containing 5'UTR IB and 5'UTR I'-B to regulate the expression of the target gene, respectively. The target gene is the gene encoding the B.1.617.2 spike protein (SEQ ID NO: 13). The plasmids were named Delta 13 and Delta 24, respectively. mRNA was obtained by PCR transcription and purification (the I'-Delta24-B mRNA sequence without the cap is shown in SEQ ID NO: 57). The prepared mRNA was then transfected into 293T cells, and the expression of the B.1.617.2 spike protein was detected by the Western blotting method in Example 2. Grayscale scanning was performed using Image software, and the grayscale value was calculated. The expression level of sample 1 (Delta 13) was calculated as 1. After normalization, the ratios shown in Table 8 were obtained.

[0429] The results are shown in Figures 6A and 6B and Table 8. As shown, regardless of whether mRNA was prepared using a small plasmid extract (without endotoxin removal) or a large plasmid extract (with endotoxin removal) as a template, the expression level of the spike protein in the construct containing the point mutation in 5'UTR I was greater than that in the construct containing 5'UTR I. Therefore, the point mutation modification of 5'UTR I in Example 3 effectively improved the expression of heterologous proteins.

[0430] Table 8. Expression levels of target genes under the regulation of IB and I'-B UTR (Western blot detection)

[0431] Example 4: Detection of mRNA expression of different target genes under the regulation of 5'UTR I'

[0432] The target gene was replaced by enzyme digestion, retaining 5'UTR I' and 3'UTR B, and plasmids encoding the B.1.617.2 (Delta) spike protein gene (SEQ ID NO: 13) and the B.1.1.529 (Omicron) spike protein gene (SEQ ID NO: 15) were constructed. The target gene sequences contained in the plasmids were SEQ ID NO: 13 and SEQ ID NO: 15, respectively, both of which were codon-optimized sequences, encoding the target protein sequences shown in SEQ ID NO: 12 and SEQ ID NO: 14. mRNA was prepared and purified using the method of Example 1, and the target protein was expressed by lipofectamine. TM 2 μg of mRNA was transfected into 293T cells at 2000 μg, and the cell supernatant was collected after 2 days. The protein blotting method in Example 2 was used to detect the expression of B.1.617.2 spike protein mRNA (named Delta 13) under IB regulation, B.1.617.2 spike protein mRNA (named Delta 24) under I'-B regulation, and B.1.1.529 spike protein mRNA (named Omicron 24) under I'-B regulation. The sequences of Delta 24 mRNA and Omicron 24 mRNA without a cap structure are shown in SEQ ID NO: 57 and SEQ ID NO: 58, respectively. Grayscale scanning was performed using Image software, and the grayscale value was calculated. The expression level of Delta 13 was set as 1. After normalization, the ratios shown in Table 9 were obtained.

[0433] Figures 7A and 7B show that under the combined regulation of the I'-B UTRs, both the new coronavirus genes B.1.617.2 and B.1.1.529 can be efficiently expressed. This suggests that 5'UTR I' has versatility and can initiate efficient expression of different target genes. Comparing 5'UTR I and I', the expression level of Delta 24 spike protein is significantly higher than that of Delta 13 spike protein, suggesting that point mutation modification of 5'UTR I' effectively improves protein expression efficiency. This result further confirms the conclusion of Example 3.

[0434] Table 9. Expression levels of target genes under combined regulation of IB and I'-B UTRs (Western blot detection)

[0435] Example 5. Detection of luciferase expression under the regulation of the UTR combination of I'-B

[0436] A vector containing a luciferase CDS sequence (SEQ ID NO: 26) was constructed, comprising the same T7 promoter (SEQ ID NO: 17) and polyA tail as in the aforementioned vector containing the new crown gene. Three vectors Luc, Luc13 and Luc24 with different UTRs were constructed respectively, and the UTRs contained in the vectors are shown in Table 10. Among them, the 5'UTR and 3'UTR combination of BNT162b2 in Luc was used as a control, which was derived from CN113521269A. The mRNA containing the cap structure was synthesized by in vitro transcription using the same method as in Example 1, and transfected in vitro. After collecting the supernatant, luciferase substrate was added for detection, and the plate was read. The results are shown in Table 11 and Figure 8.

[0437] Table 10. Vector structure

[0438] Table 11. Luciferase expression levels under the regulation of I'-B and IB Note: Parameters are expressed in relative light units (RLU).

[0439] The results showed that the expression of luciferase protein under the regulation of 5'UTR I' after point mutation was higher than that under 5'UTR I. Compared with the 5'UTR and 3'UTR combination of BNT162b2 in the Luc control, the IB combination disclosed herein resulted in higher expression of the target gene, and the I'-B combination significantly increased the expression of the target gene. The test results using luciferase as the target gene also once again demonstrated that both 5'UTR I and 5'UTR I' can universally regulate the efficient expression of any target protein.

[0440] Example 6: Detection of luciferase expression regulated by 5'UTR I' truncations and mutants

[0441] 6.1 The 5' end of 5'UTR I' was continuously truncated, and the efficiency of 5'UTR I' truncation of different lengths in regulating protein expression was analyzed by bioinformatics methods (Nat Biotechnol. 2019 Jul; 37 (7): 803-809.). The relative MRL values ​​of 5'UTR I' truncation and 5'UTR I' were calculated, and the results are shown in Table 12 below. As shown in Table 12, continuous truncation of the nucleotide sequence at the 5' end of 5'UTR I' does not cause a significant decrease in the MRL value, indicating that 5'UTR I' truncation can retain the functional activity of regulating the expression of the target protein. The nucleotide sequence at the 3' end of the 5'UTR I' truncation shown in SEQ ID NO: 153 was continuously truncated, and the relative MRL values ​​of the truncation after 3' end truncation and the sequence shown in SEQ ID NO: 153 were calculated. The results are shown in Table 13. As shown in Table 13, 3' end truncation did not significantly affect the regulatory efficiency of the 5'UTR I' truncation.

[0442] Table 12 Relative MRL values ​​of 5'UTR I' truncations and 5'UTR I'

[0443] Table 13 Relative MRL values ​​of 5'UTR I' truncations after 3' truncation and without truncation

[0444] 6.2 Sixteen 5'UTR I' truncations of different lengths (SEQ ID NOs: 28-40, CTATAAT) and two A→C and A→T point mutations different from the A→G point mutation (SEQ ID NOs: 42-43) were constructed and synthesized by Suzhou Jinweizhi Co., Ltd. The 16 synthetic sequences were then digested with HindIII and ScaI, ligated, and inserted into Luc 24 of Example 5 to obtain the corresponding luciferase 5'UTR I' truncation and point mutation constructs, named LUC1-16. The corresponding 5'UTR I' truncation (1-I' to 14-I') and mutant (15-I' to 16-I') sequences are shown in SEQ ID NOs: 63-78. The mRNA containing the cap structure was synthesized by in vitro transcription using the same method as in Example 1. After 24 h of in vitro transfection of 293T cells, luciferase substrate was added for detection and the plate was read. The results are shown in Figure 9. The expression of luciferase mediated by Luc24 (combination of I'-B) and its 5'UTR I' truncated and mutant forms was significantly higher than that of Luc (5' and 3'UTR of BNT162b2). 5'UTR I' truncation can maintain the activity of 5'UTR I' in regulating the expression of the target protein, wherein some 5'UTR I' truncations (1-I', 2-I', 3-I', 4-I', 5-I', 6-I', 7-I', 9-I', 10-I', 11-I', 13-I') have increased activity in regulating the expression of the target protein. At the same time, the mutants 15-I' and 16-I' of 5'UTR I' made the expression level of the target gene better than 5'UTR I', indicating that truncation of the 5' end of 5'UTR I' or point mutation inside it can further enhance the functional activity of 5'UTR in regulating the expression of the target gene.

[0445] Example 7: Differences in influenza HA mRNA expression levels under control 5'UTR and 5'UTR I'

[0446] The target gene was replaced by enzyme digestion, retaining 5'UTR I' and 3'UTR B, and plasmids encoding the gene of influenza A virus H1N1 (A / Wisconsin / 588 / 2019) HA protein (SEQ ID NO: 83), the gene of influenza A virus H3N2 (A / Cambodia / e0826360 / 2020) HA protein (SEQ ID NO: 84), the gene of influenza B virus (Washington / 02 / 2019) HA protein (SEQ ID NO: 85), and the gene of influenza B virus (Phuket / 3073 / 2013) HA protein (SEQ ID NO: 86) were constructed, respectively. The target gene sequences contained in the plasmids are SEQ ID NOs: 87-90, all of which are codon-optimized sequences. Four HA CDS sequences encoding SEQ ID NOs: 83-86 were synthesized with reference to the 5' and 3' UTR sequences (SEQ ID NOs: 91-92) of patents WO2022 / 245888A1 and WO2022 / 150717A1. mRNA was prepared and purified using the method of Example 1 and then purified by Lipofectamine TM 2000 mRNA 1 μg was transfected into 293T cells, and cell lysates were collected after 1 day. The expression of four influenza HA protein mRNAs under I'-B regulation was detected by the Western blotting method in Example 2, wherein the primary antibody used influenza A virus Hemagglutinin / HA antibody (Sino Biology, 86001-RM01) and influenza B virus Hemagglutinin / HA antibody (Sino Biology, 11053-R004), and the secondary antibody used HRP-linked anti-rabbit IgG (Transgene, HS101). The results are shown in Figures 10 and 11. Compared with the control 5'UTR, the expression levels of the four influenza HAs under 5'UTR-I' regulation were significantly higher.

[0447] The following is a partial sequence of the present disclosure:

Claims

1. A nucleic acid construct comprising: (a) an open reading frame (ORF), and (b) 5' untranslated region element (5'UTR); in, The 5'UTR is derived from the ARHGAP gene; Preferably, the ARHGAP is ARHGAP15; More preferably, the 5'UTR comprises the nucleotide sequence shown in SEQ ID NO: 44 or a truncation thereof.

2. The nucleic acid construct according to claim 1, wherein The 5'UTR comprises at least one point mutation that can be used to inhibit the initiation of translation of ATG within the UTR; Preferably, the point mutation is selected from mutations at any one or more of the A, T or G sites of the ATG sequence in the 5'UTR; More preferably, the mutation is from A to G, C or T.

3. The nucleic acid construct according to claim 1 or 2, wherein The 5'UTR truncation still maintains the function of regulating the expression of the protein encoded by the ORF; or, the 5'UTR truncation has an enhanced function of regulating the expression of the protein encoded by the ORF compared to the natural 5'UTR; Preferably, the truncation of the 5'UTR truncation comprises: deleting a continuous nucleotide sequence at the 5' end in the sequence direction from the 5' to the 3' end; and / or deleting a continuous nucleotide sequence at the 3' end in the sequence direction from the 3' to the 5' end.

4. The nucleic acid construct according to any one of claims 1 to 3, wherein The 5'UTR truncation is a sequence from the 5' to the 3' end in which the continuous nucleotide sequence at the 5' end is missing; and / or a sequence from the 3' to the 5' end in which the continuous nucleotide sequence at the 3' end is missing; Preferably, the 5'UTR truncation comprises at least 5 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 44, and more preferably comprises at least 7 consecutive nucleotide sequences of the sequence shown in SEQ ID NO: 2; Preferably, the nucleotide at the 5' end of the 5'UTR truncation is a nucleotide at any position of position 1-57 according to natural counting of the sequence shown in SEQ ID NO: 44, more preferably a nucleotide at any position of position 1-13 or position 17-29 according to natural counting of the sequence shown in SEQ ID NO: 2; Preferably, the 5'UTR truncation comprises CTATAAT or the nucleotide sequence shown in SEQ ID NO:

193.

5. The nucleic acid construct according to any one of claims 1 to 3, wherein The 5'UTR comprises a nucleotide sequence shown in any one of SEQ ID NOs: 2, 28-43, 76, 137-196, or comprises CTATAAT; or a nucleotide sequence having at least 80% identity with any of the aforementioned sequences.

6. The nucleic acid construct according to any one of claims 1 to 5, further comprising: (c) 3' untranslated region element (3'UTR); Preferably, the 3'UTR comprises a 3'UTR derived from any one of the genes HBB, ARHGAP, CORO1A or HPX; More preferably, the 3'UTR comprises a 3'UTR derived from ARHGAP15.

7. The nucleic acid construct according to claim 6, wherein The 3'UTR comprises a nucleotide sequence shown in any one of SEQ ID NOs: 7-10, or the 3'UTR comprises a nucleotide sequence having at least 80% identity with any one of SEQ ID NOs: 7-10.

8. The nucleic acid construct according to any one of claims 1 to 7, further comprising: (d) Polyadenylic acid (poly-A) tail.

9. The nucleic acid construct according to claim 8, wherein The poly-A tail is selected from HGH polyA, SV40 polyA, BGH polyA, rbGlob polyA or SV40late polyA; Preferably, the poly-A tail comprises a nucleotide sequence as shown in SEQ ID NO: 16 or SEQ ID NO: 135, or a nucleotide sequence having at least 80% identity thereto.

10. The nucleic acid construct according to any one of claims 1 to 9, wherein The ORF encodes a viral antigen; preferably, the ORF encodes a coronavirus antigen or an influenza virus antigen; The coronavirus is preferably SARS-COV-2, and the coronavirus antigen is preferably a spike protein; More preferably, the spike protein is selected from the spike protein of any virus strain of SARS-COV-2, SARS-COV-2 Alpha, SARS-COV-2 Beta, SARS-COV-2 Gamma, SARS-COV-2 Kappa, SARS-COV-2 Delta or SARS-COV-2 Omicron; The influenza virus is preferably influenza A virus or influenza B virus, and the antigen is hemagglutinin protein (HA) and / or neuraminidase (NA); More preferably, the influenza virus antigen is selected from the hemagglutinin protein and / or neuraminidase of any one of influenza A virus H1N1, influenza A virus H3N2, influenza B virus Victoria, and influenza B virus Yamagata.

11. The nucleic acid construct according to any one of claims 1 to 10, wherein The polypeptide sequence encoded by the ORF comprises the amino acid sequence shown in any one of SEQ ID NOs: 12, 14, 21, 23, 25, 80, 83-86, 98-101 and 136; Preferably, the ORF comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 13, 15, 20, 22, 24, 81, 87-90, 97, 102-105, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with any one of SEQ ID NOs: 13, 15, 20, 22, 24, 81, 87-90, 97, 102-105.

12. The nucleic acid construct as described in any of the preceding items, comprising a nucleotide sequence as shown in SEQ ID NO: 18-19 or a nucleotide sequence having at least 80% identity thereto.

13. An RNA molecule comprising: (a) Open reading frame (ORF); (b) 5' untranslated region element (5'UTR); and (c) 3' untranslated region element (3'UTR); wherein the 5'UTR is selected from the 5'UTR derived from any one of ARHGAP, HSPB1, HBB or CCL13 genes, and the 3'UTR is selected from the 3'UTR derived from any one of HBB, ARHGAP, CORO1A or HPX genes; The ARHGAP is preferably ARHGAP15, and the 5'UTR preferably comprises the nucleotide sequence shown in SEQ ID NO: 79 or a truncation thereof.

14. The RNA molecule of claim 13, wherein the 5'UTR and 3'UTR are selected from any one of the following combinations: 1) The 5'UTR is derived from the 5'UTR of ARHGAP, and the 3'UTR is derived from the 3'UTR of HBB, ARHGAP, CORO1A or HPX; 2) the 5'UTR is derived from the 5'UTR of HSPB1, and the 3'UTR is derived from the 3'UTR of any of HBB, ARHGAP, CORO1A, or HPX; 3) the 5'UTR is derived from the 5'UTR of HBB, and the 3'UTR is derived from the 3'UTR of any of HBB, ARHGAP, CORO1A, or HPX; 4) the 5'UTR is derived from the 5'UTR of CCL13, and the 3'UTR is derived from the 3'UTR of any of HBB, ARHGAP, CORO1A, or HPX; Preferably, The 5'UTR of ARHGAP comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 45-46, 63-75, 77-78, CUAUAAU, or CUAUAAU, or a nucleotide sequence having at least 80% identity with any of the foregoing sequences; The 5'UTR derived from HSPB1 comprises a nucleotide sequence as shown in SEQ ID NO: 47 or a nucleotide sequence having at least 80% identity thereto; The 5'UTR derived from HBB comprises a nucleotide sequence as shown in SEQ ID NO: 48 or a nucleotide sequence having at least 80% identity thereto; The 5'UTR derived from CCL13 comprises a nucleotide sequence as shown in SEQ ID NO: 49 or a nucleotide sequence having at least 80% identity thereto; The 3'UTR derived from HBB comprises a nucleotide sequence as shown in SEQ ID NO: 50 or having at least 80% identity thereto; The 3'UTR derived from ARHGAP comprises a nucleotide sequence as shown in SEQ ID NO: 51 or having at least 80% identity thereto; The 3'UTR derived from CORO1A comprises a nucleotide sequence as shown in SEQ ID NO:52 or a nucleotide sequence having at least 80% identity thereto; The HPX-derived 3'UTR comprises a nucleotide sequence as shown in SEQ ID NO: 53 or a nucleotide sequence having at least 80% identity thereto.

15. The RNA molecule according to any one of claims 13 to 14, wherein The ORF encodes a viral antigen; preferably, the ORF encodes a coronavirus antigen or an influenza virus antigen; The coronavirus is preferably SARS-COV-2, and the coronavirus antigen is preferably a spike protein; More preferably, the spike protein is selected from the spike protein of any virus strain of SARS-COV-2, SARS-COV-2 Alpha, SARS-COV-2 Beta, SARS-COV-2 Gamma, SARS-COV-2 Kappa, SARS-COV-2 Delta or SARS-COV-2 Omicron; or, The influenza virus is selected from influenza A virus or influenza B virus, and the influenza virus antigen is hemagglutinin protein (HA) and / or neuraminidase (NA); More preferably, the influenza virus antigen is selected from the hemagglutinin protein and / or neuraminidase of any one of influenza A virus H1N1, influenza A virus H3N2, influenza B virus Victoria, and influenza B virus Yamagata.

16. The RNA molecule of claim 15, wherein The polypeptide sequence encoded by the ORF comprises the amino acid sequence shown in any one of SEQ ID NOs: 12, 14, 21, 23, 25, 80, 83-86, 98-101 and 136; Preferably, the nucleotide sequence of the ORF comprises any one of SEQ ID NOs: 54-55, 59-61, 82 and 126-134, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with any one of SEQ ID NOs: 54-55, 59-61, 82, 126-134.

17. The RNA molecule of any one of claims 13 to 16, further comprising: (d) Polyadenylic acid (poly-A) tail.

18. The RNA molecule of claim 17, wherein The poly-A tail is selected from HGH polyA, SV40 polyA, BGH polyA, rbGlob polyA or SV40late polyA; Preferably, the poly-A tail comprises the nucleotide sequence shown in SEQ ID NO: 56 or SEQ ID NO: 135 or a nucleotide sequence having at least 80% identity thereto.

19. The RNA molecule of any one of claims 13 to 18, comprising (a) an open reading frame (ORF), (b) a 5' untranslated region element (5'UTR), (c) a 3' untranslated region element (3'UTR), and (d) a polyadenylic acid (poly-A) tail; Preferably, the RNA molecule comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 57-58, 106-125.

20. The RNA molecule of any one of claims 13 to 19, further comprising: (e) 5' cap structure (5'Cap).

21. The RNA molecule of claim 20, wherein The 5'Cap is selected from Cap0, Cap1, Cap2, Cap3, Cap4, ARCA, modified ARCA, inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine and 2-azido-guanosine; Preferably, the 5'Cap is selected from ARCA, 3'OMe-m7G(5')ppp(5')G, m7G(5')ppp(5')(2'OMeA)pU, m7Gppp(A2'O-MOE)pG, m7G(5')ppp(5')( 2'OMeA)pG, m7G(5')ppp(5')(2'OMeG)pG, m7(3'OMeG)(5')ppp(5')(2'OMeG)pG or m7(3'OMeG)(5')ppp(5')(2'OMeA)pG; Preferably, the 5'Cap is m7G(5')ppp(5')(2'OMeA)pG.

22. The RNA molecule of any one of claims 13 to 21, which is mRNA.

23. The RNA molecule of any one of claims 13 to 22, further comprising one or more modifications, Preferably, the modification comprises backbone modification, sugar modification, base modification and / or lipid modification; More preferably, the base modification is a pseudouridine modification.

24. An RNA molecule comprising a nucleotide sequence as shown in any one of SEQ ID NOs: 54-55, 59-61, 82, 126-134, or a nucleotide sequence having at least 80% identity with any one of SEQ ID NOs: 54-55, 59-61, 82, 126-134; Preferably, the RNA molecule further comprises one or more modifications, more preferably, the modification is a pseudouridine modification.

25. Use of the nucleic acid construct of any one of claims 1 to 12, or the RNA molecule of any one of claims 13 to 24, in any of the following: (1) preparing a vaccine; (2) encoding a viral antigen in vivo or in vitro in a subject; (3) preparing a drug that encodes a viral antigen in vivo or in vitro in a subject; (4) for preparing a drug.

26. A vaccine comprising the RNA molecule of any one of claims 13 to 24, preferably, the RNA molecule encodes one or more antigens of one or more viral strains.

27. A vector comprising the nucleic acid construct according to any one of claims 1 to 12, or the RNA molecule according to any one of claims 13 to 24.

28. A host cell comprising the vector of claim 27.

29. A method for preparing an RNA molecule according to any one of claims 13 to 24, comprising: The nucleic acid construct according to any one of claims 1 to 12 or the vector according to claim 27 is reverse transcribed to obtain an RNA molecule; preferably, the method further comprises adding a 5' Cap to the 5' end of the RNA molecule.

30. A delivery system comprising the nucleic acid construct of any one of claims 1 to 12 or the RNA molecule of any one of claims 13 to 24, wherein: The delivery vehicle of the delivery system is a cationic lipid delivery particle, preferably, the delivery vehicle is a nanolipid particle.

31. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier, diluent or excipient, and Select any of the following: The nucleic acid construct of any one of claims 1 to 12, the RNA molecule of any one of claims 13 to 24, the vaccine of claim 26, and / or the delivery system of claim 30.

32. A product or kit comprising the nucleic acid construct of any one of claims 1 to 12, the RNA molecule of any one of claims 13 to 24, the vaccine of claim 26, the delivery system of claim 30, and / or the pharmaceutical composition of claim 31.

33. A use for preparing a medicament for treating and / or preventing a disease, comprising administering an effective amount of the nucleic acid construct of any one of claims 1 to 12, the RNA molecule of any one of claims 13 to 24, the vaccine of claim 26, the delivery system of claim 30, the pharmaceutical composition of claim 31, and / or the product or kit of claim 32 to a subject in need thereof; the disease is a viral infectious disease or a respiratory disease associated with viral infection; Preferably, the virus is a coronavirus or an influenza virus, and the virus is more preferably SARS-CoV-2, influenza A virus or influenza B virus; Preferably, the viral infection-related respiratory diseases include simple infection, fever, cough, pharyngitis, rhinitis, headache, pneumonia, acute respiratory tract infection, severe acute respiratory tract infection (SARI), hypoxic respiratory failure, acute respiratory distress syndrome, sepsis, septic shock, and severe acute respiratory syndrome (SARS).

34. A method for treating and / or preventing a disease, comprising administering to a subject in need thereof an effective amount of the nucleic acid construct of any one of claims 1 to 12, the RNA molecule of any one of claims 13 to 24, the vaccine of claim 26, the delivery system of claim 30, the pharmaceutical composition of claim 31, and / or the product or kit of claim 32; the disease is a viral infectious disease or a respiratory disease associated with viral infection; Preferably, the virus is a coronavirus or an influenza virus, and more preferably the virus is SARS-CoV-2, influenza A virus or influenza B virus; Preferably, the viral infection-related respiratory diseases include simple infection, fever, cough, pharyngitis, rhinitis, headache, pneumonia, acute respiratory tract infection, severe acute respiratory tract infection (SARI), hypoxic respiratory failure, acute respiratory distress syndrome, sepsis, septic shock, and severe acute respiratory syndrome (SARS).

35. A method for inducing a neutralizing antibody response and / or a T cell immune response in a subject, comprising administering to a subject in need thereof an effective amount of the nucleic acid construct of any one of claims 1 to 12, the RNA molecule of any one of claims 13 to 24, the vaccine of claim 26, the delivery system of claim 30, the pharmaceutical composition of claim 31, and / or the product or kit of claim 32; Preferably, the neutralizing antibody response is a neutralizing antibody response against viral antigens, and the T cell immune response includes CD4+ and / or CD8+ T cell immune responses; Preferably, the virus is a coronavirus or an influenza virus, and more preferably the virus is SARS-CoV-2, influenza A virus or influenza B virus.